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1 Abbreviations 
ActA  Activin A 
AMIG  Austrian Mesothelioma Interest Group 
AQP1  Aquaporin 1 
AUVA  Allgemeine Unfallversicherungs Anstalt 
BAL  Bronchoalveolar lavage 
BAP1  BRCA1(breast cancer 1)-associated protein1 
Bcl-2  B-cell lymphoma-2 
Bg8  Blood group 8 
BSC  Best supportive care 
C4d  Complement component 4d 
CDH8  Cadherin 8 
CDKN2A–ARF  Cyclin-dependent kinase inhibitor 2A 
CFAP45  Cilia and Flagella Associated Protein 45 
CHT  Chemotherapy 
CI  Confidence interval 
CNV  Copy number variations 
COX-2  Cyclooxygenase-2 
CRO  Croatia 
CRP  C-reactive protein 
CT  Computed tomography 
DDX3X  DEAD-box helicase 3 
DDX51  DEAD-Box Helicase 51 
DFS  Disease-free survival 
DHFR  Dihydrofolate reductase 
DPP10  Dipeptidyl-peptidase 10 
EBUS  Endobronchial ultrasound 
EE  Environmental exposure 
EGFR  Epidermal growth factor receptor 
ELISA  Enzyme-linked immunosorbent assay 
EMT  Epithelial-to-mesenchymal transition 
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EORTC  European Organization for Research and Treatment of Cancer 
EPP  Extrapleural pneumonectomy 
ERCC1  Excision repair cross-complementation group 1 
ERS  European Respiratory Society 
ESTS  European Society of Thoracic Surgeons 
EUS  Esophageal ultrasound 
FDG-PET  Fluorodeoxyglucose positron emission tomography 
FFPE  Formalin fixed paraffin embedded 
FNA  Fine-needle aspiration 
FSH  Follicle-stimulating hormone 
Gas-6  Growth arrest signal-6 
GPS  Glasgow Prognostic Score 
Gy  Gray 
HE  Hematoxylin/eosin 
HIOC  Hyperthermic intraoperative chemotherapy 
HR  Hazard ratio 
HUN  Hungary 
HV  Healthy volunteers 
IARC  International Agency for Research on Cancer 
IASLC  International Association for the Study of Lung Cancer 
IgM  Immunoglobulin M 
IHC  Immunohistochemistry 
IMIG  International Mesothelioma Interest Group 
IMRT  Intensity modulated radiotherapy 
IRR  Incidence rate ratio 
MAC  Membrane attack complex 
MAP2K6  Mitogen-activated protein kinase kinase 6 
MAPK  Mitogen-activated protein kinase 
MAPS  Mesothelioma Avastin Cisplatin Pemetrexed Study 
MARS  Mesothelioma and Radical Surgery 
MASP  MBL-associated serine protease 
MBL  Mannan-binding lectin 
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MCR  Macroscopic complete resection 
MIF  Migration inhibitory factor 
MMT  Multimodal treatment 
MOC-31  Mouse Monoclonal Primary Antibody 31 
MPM  Malignant pleural mesothelioma 
mTOR  Mechanistic target of rapamycin 
NA  Not available 
NCCN  National Comprehensive Cancer Network 
NF2  Neurofibromin type 2 
NFRKB  Nuclear factor related to kappa B binding protein 
NKX6-2  NK6 homeobox 2 
NLR  Neutrophil-to-lymphocyte ratio 
NLRP3  NOD-like receptor family, pyrin domain containing 3 
NMPD  Non-malignant pleural diseases 
NSCLC  Non-small cell lung cancer 
nTiO2  Nano size titanium dioxide particles 
NTS  Neurotensin 
NTSR1  Neurotensin receptor 1 
OPN  Osteopontin 
OR  Odds ratio 
OS  Overall survival 
P/D  Pleurectomy/decortication 
PCBD2  Pterin-4-alpha-carbinolamine dehydratase 2 
PDT  Intracavitary photodynamic therapy 
PFS  Progression free survival 
PLR  Platelet-to-lymphocyte ratio 
PS  Performance status 
RNS  Reactive nitrogen species 
ROS  Reactive oxygen species 
RT  Radiotherapy 
RTK  Receptor-tyrosine kinase 
RYR2  Ryanodine receptor 2 
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SCLC  Small cell lung cancer 
SD  Standard deviation 
SETD2  SET domain containing 2 
SETDB1  SET Domain Bifurcated 1 
SMART  Surgery for Mesothelioma After Radiation Therapy 
SMRP  Serum-soluble mesothelin family proteins, soluble mesothelin-related peptide 
SV40  Simian virus 40 
TBNA  Transbronchial needle aspiration 
TKI  Tyrosine-kinase-inhibitor 
TNM  Tumor node metastasis 
TS  Thymidylate synthase 
ULK2  Unc-51 Like Autophagy Activating Kinase 2 
US  United States 
VATS  Video-assisted thoracic surgery 
VATS-PP  VATS partial pleurectomy 
VEGF  Vascular endothelial growth factor 
WHO  World Health Organization 
WT-1  Wilms-Tumor Protein 1 
  
 - 9 - 
 
2 Introduction 
2.1 Malignant pleural mesothelioma 
2.1.1 Epidemiology 
In 2012, 14.1 million new cancer cases and 8.2 million cancer deaths occurred 
worldwide. Among these, lung and breast cancer are diagnosed most frequently and 
represent the leading causes of cancer death in men and women, overall and in less 
developed countries. However, in more developed countries, prostate cancer accounts 
for the most diagnosed malignancy and lung cancer represents the leading cause of 
cancer death in women [1]. In general, global cancer burden will shift to less developed 
countries within the next decades due to an increasing prevalence of risk factors and 
growing and aging populations [2]. By 2012, less developed countries accounted for 
only 57% of global cancer cases and 65% of cancers deaths, due to more frequent other 
causes of death, such as infection, and the younger age structure [1, 2].  
Worldwide, liver, stomach and colorectal cancers are additionally frequently diagnosed 
among men, whereas stomach, cervical and colorectal cancer are frequent among 
women [1]. In more developed countries, prostate, colorectal, breast and lung cancer 
incidences tend to be higher, whereas liver, stomach and cervical cancer are more 
frequently diagnosed in less developed countries. These trends are predominantly 
attributable to infectious diseases, being more prevalent in less developed countries [3]. 
Additional risk factors for most frequently diagnosed cancers worldwide include 
smoking (lung, colorectal, stomach, liver cancer), overweight and physical inactivity 
(breast, colorectal). By applying effective risk factor prevention strategies (i.e. tobacco 
control, vaccination) and the broad use of early detection tests, a substantial proportion 
of cancer cases could be effectively prevented [1]. Besides highly prevalent cancer 
types, some less frequently diagnoses malignancies are gradually on rise and research 
must focus on prevention, early detection and new therapeutic targets in these diseases 
as well.  
Malignant pleural mesothelioma (MPM) is a rare but devastating malignancy, arising 
from the pleural space. The tumor is known to be a rare disease; however, its incidence 
is increasing worldwide, probably as a result of widespread exposure to asbestos, 
known to be the main risk factor for MPM development. There is a significant variation 
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of MPM incidence among different areas worldwide. It ranges between 7 per million 
inhabitants in Japan and 40 per million in Australia [4]. The highest mesothelioma 
incidence rates are reported from some countries in Europe (UK, Italy, The Netherlands, 
Malta, Belgium) and in Oceania (Australia, New Zealand). In the UK for instance, the 
annual number of deaths from MPM increased continuously, being 153 in 1968 and 
2.360 in 2010. In 2011, the numbers of deaths were 2.291. In the period of 2000-2011, 
incidence rates in the UK were 3.3-3.6 per 100,000 among men, and 0.5-0.7 among 
women [5]. In Italy, incidence in 2011 among men was 3.5 and 1.25 per 100,000 in men 
and women, respectively, and wide differences are noted among different geographic 
areas within the country [6]. Intermediate incidence rates are reported from a group of 
countries including large parts of Europe and the United States (US) [7, 8]. In Germany, 
7.547 malignant mesotheliomas were reported to cancer registries diagnosed between 
2009 and 2013, 90% of those being located in the chest. On average, 1.198 men and 312 
women were affected each year. Regional clusters were predominantly located to the 
seaports of West Germany [9]. In the US, between 2003 and 2008 over 3000 cases were 
diagnosed each year, with a maximum of 3284 in 2005. In this period, the incidence 
was 1.93 per 100,000 among men and 0.41 among women [7]. Low incidence/mortality 
rates are reported from various countries of Central Europe, Ireland, Spain, and from 
several countries of Asia [10-12]. In Austria, there have been 276 cases of MPM 
approved by the “Allgemeine Unfallversicherungsanstalt – General accident insurance 
company” (AUVA) as being caused occupationally between 2010 and 2015. Of these, 
53 were approved in 2014 only. In contrast to this, ten asbestos-related MPM cases 
were documented in 1995 and 41 in 2005. However, there is still uncertainty about the 
number of MPM cases not being reported to the AUVA and currently, there is no 
register on non-occupational MPM in Austria [12]. A comparison of the incidence of 
MPM worldwide and in Austria is depicted in Figure 1.  
In Europe, the average incidence is 2 per 100.000 inhabitants. The frequency is highly 
dependent on the amount of asbestos removal, asbestos import and industrialization and 
the peak incidence is to be expected around 2020 due to the long latency period [4, 13]. 
In the US, MPM peaked in the 1980s to 1990s and is now plateauing. In men, incidence 
has been stable at 1.8 cases per 100.000 for the past 10 years, with peak values in the 
early 1990s (2.5 cases per 100,000 people), while in women, rates were 0.4 cases per 
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100.000 people, and did not change substantially over time [14]. Due to the long latency 
period and recent asbestos banning efforts, a possible reduction in the MPM health 
burden and a reduction in the number of newly diagnosed cases is expected in the near 
future, at least in developed countries [15]. 
 
 
Figure 1: Incidence of MPM in Austria compared to worldwide MPM incidence ([8]). Data are given as 
age-standardized rates per 100.000 in men. 
Currently, however, MPM incidence is still increasing in most countries of the world, 
and a decrease can only be seen in countries where asbestos control measures were 
taken [5, 14]. Thus, the overall worldwide epidemic is still increasing and in countries 
that still produce and/or commercially use asbestos, such as China, India, Russia, a 
sharp rise in incidence might be expected in the future [16-18]. 
 
2.1.2 Etiology 
2.1.2.1 Asbestos-related MPM development 
Previous asbestos exposure is known to be the main risk factor for the development of 
MPM [19, 20]. Asbestos is classified into two main groups, the serpentines and the 
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amphiboles. The serpentines consist of one type, chrysotile (95% of asbestos in 
commercial use), with a characteristic short and curly fiber, also referred to as “white 
asbestos” due to its white color. The amphiboles, with straight, longer fibers, include 
crocidolite or “blue asbestos”, amosite, tremolite, actinolite and anthophyllite. These six 
fibers are collectively summarized as “asbestos” due to regulatory issues and their 
common known health risk [21, 22]. The risk of MPM development has shown to be 
dependent on the fiber type, as shorter fibers are assumed to be less carcinogenic [23]. 
Even though some studies claimed that chrysotile could generate mesothelioma only if 
it was contaminated with amphiboles [24], it has been clearly shown that chrysotile is 
an important carcinogen and risk factor for MPM development, and also for lung cancer 
[25]. Thus, in the current international perception, all types of asbestos are classified as 
class I carcinogens, according to the World Health Organization (WHO) and the 
International Agency for Research on Cancer (IARC). Furthermore, it is well 
recognized that exposure to asbestos is the major cause of both pleural and peritoneal 
mesothelioma, which resulted in the banning of asbestos production and import in 
several European countries at various time-points after 1970, and in the European Union 
as late as 2005 [4, 22]. 
Asbestos exposure is typically labor-dependent and is recognized as an occupational 
disease in many countries [8]. The mean latency period between exposure to asbestos 
and the onset of symptoms has been reported to be up to 40 years, and 99 % of cases 
show a latency of more than 15 years [26]. In most epidemiological studies, MPM is 
more common in men and some studies have claimed that its occurrence is correlated 
with sex. However, other studies have shown that MPM development is to be related to 
asbestos exposure and, typically, there is low asbestos exposure in women because the 
occupations associated with exposure are traditionally carried out by men [27]. 
Additionally, women with MPM have shown to exhibit a threefold better overall 
survival (OS) than men [14]. More recently, a shift has been observed from asbestos-
removal workers to professionals involved in post-construction work, e. g., electricians, 
plumbers, or heat protection technicians [19]. 
There is a clear correlation between the amount of asbestos exposure and the incidence 
of MPM, however, no safe lower threshold has been identified. Furthermore, there is an 
increasing incidence of non-occupational asbestos diseases among housewives and 
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family members of asbestos workers, due to cleaning of contaminated work clothes, as 
well as a high environmental impact in the vicinity of mining and processing facilities 
[8, 28, 29]. In a certain region of Italy, an epidemic of MPM was registered among 
inhabitants who were never exposed to local asbestos factories, whereas a high 
proportion of cases had only one risk factor: living close to an asbestos cement factory. 
The calculated risk was very high for those living <500 m from the factory and the fiber 
burden in the lungs of deceased cases was 10-fold that in those from other areas [30]. 
Another recent study reported a mesothelioma incidence rate ratio (IRR) of 12.92 for 
those living <500 m from an asbestos cement plant in Barcelona, Spain, while the ratios 
decreased to 0.70 and 0.23 for those living 500-2000 m and >2000-10000 m from the 
plant, respectively [31]. Accordingly, a dose dependent relation between asbestos 
exposure and risk for MPM development is well perceived. 
Despite worldwide efforts to ban asbestos production and commercial use, there is still 
the additional risk for environmental exposure, whose impact on MPM development is 
not well studied. The quantification of environmental associated MPM occurrence is 
furthermore limited mainly by the lack of reliable assessment of type and amount of 
exposure [15, 32]. One major feature of environmental exposure associated MPM is a 
general higher disease burden in women than in men. The ratio (male:female) in several 
studies is often close or less than 1 (Figure 2). 
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Figure 2: Male to female ratios among malignant mesothelioma cases reporting overall exposure 
(occupational and environmental) and environmental exposure (EE) to asbestos [15]. EE, environmental 
exposure 
Environmental occurrence of mesothelioma has been found in people growing up near 
natural asbestos resources (Turkey, Corsica, Cyprus) or in areas where asbestos was 
used for the whitening of house walls. In this regard, erionite, an asbestos-like mineral 
from the soil, was revealed as the main factor of mesothelioma in young people in some 
villages in Turkey, where more than 50% of inhabitants died from MPM [33]. In this 
area, the average annual mesothelioma incidence rates are 114.8 per 100,000 for men 
and 159.8 per 100,000 for women, or 88.3 times greater in men and 799 times greater in 
women, respectively, in comparison to world background incidence rates [34, 35]. 
Another study revealed that whitewashing the houses with soft tremolite in Metsovo, 
Greece, was the reason for a high number of mesothelioma cases in young women, as 
they used to do this work [36]. 
Inhaled asbestos fibers enter the pleural space through the alveoli or retrograde through 
the lymphatic vessels, causing cytotoxicity, DNA damage, frustrated phagocytosis and 
chronic inflammation (Figure 3) [37, 38]. Important key mechanisms of the mesothelial 
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cells, such as chromosomal aberrations and epigenetic changes, result in cellular 
dysfunction at gene, microRNA and protein expression levels [39, 40].  
Asbestos fibers are usually detected and entrapped by alveolar macrophages into 
lysosomes. The NOD-like receptor family, pyrin domain containing 3 (NLRP3) 
inflammasome gets activated to cleave procaspase 1 to an active form. Fibrotic nodules 
are formed by the release of cleaved and activated prointerleukin-1-beta. Consequently, 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced within 
the macrophages which ultimately cause cellular and tissue damage. Apoptosis of 
alveolar macrophages lead to the production of various cytokines such as IL-1β tumor 
necrosis factor (TNF)-α, macrophage inflammatory protein (MIP)-1/2, monocyte-
chemoattractant protein-1, and IL-8 to cause chronic inflammation and proliferation of 
collagenic fibers. Asbestos particles are then again released and newly recognized by 
nearby macrophages leading to the repetition of similar cellular response mechanisms. 
Ultimately, partially cleaved asbestos fibers are transferred to regional lymph nodes, 
particularly at the opening of lymphatic vessels. Circulating and local 
immunocompetent cells will recognize these fibers repeatedly, recurrently and 
continuously, encountering for chronic local inflammation [41-43]. 
However, the question if the MPM progenitor cell arises from a highly differentiated 
mesothelial cell or a submesothelial multipotential cell is still unresolved yet. Normal 
mesothelial cells may regenerate from normal mesothelium and by the development of 
submesothelial multipotential stem cells [44]. Moreover, recent studies showed that also 
adipocytes, circulating multipotential fibrocytes and adult bone marrow-derived stem 
cells can differentiate into both epithelial and mesenchymal cells [45]. Despite this, it is 
still further unclear, if this MPM progenitor cell might arise from the parietal pleura 
more likely than from the visceral. It has been previously hypothesized that a parietal 
origin might be more likely since cases with only parietal affection (previously staged 
as T1a (TNM-7)) have a worse survival compared to cases in stage T1b (TNM-7), 
which involves the parietal and visceral pleura, indicating that the parietal lesion is an 
earlier event [46, 47]. 
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2.1.2.2 Non-asbestos-related MPM development 
In contrast to asbestos-related MPM development, the incidence of mesothelioma 
without asbestos contact is extremely low (<1: 1 million). Potential cofactors for MPM 
occurrence besides asbestos are synthetic materials (ceramics, nanoparticles), ionizing 
radiation, and SV-40 virus infections [48]. Exposure to nanoparticles such as carbon 
nanotubes has been shown to cause MPM similar to that caused by asbestos, and thus 
has become an environmental health issue [49]. In this regard, fiber-length is an 
important parameter in triggering chronic pleural inflammation. Recently, it has been 
demonstrated that nanofibers beyond 4 µm in length are pathogenic to the pleura and 
shorter nanofibers might exhibit a potentially lower risk of cellular damage [50].  
 
 
Figure 3: Hypothesized sequence of events leading to pleural responses as a consequence of long fiber 
retention of asbestos and nanofibers at the parietal pleural stomatal openings leading to chronic 
inflammation and tumor induction [51]. 
Among nanofibers, nano size titanium dioxide particles (nTiO2) are one of the most 
commonly used metal nanoparticles in commercial products, such as cosmetics, 
sunscreens, food products, paints and drugs. nTiO2 have been shown to cause reactive 
oxygen species (ROS) leading to toxicity [52]. A recent study has shown that with 
respect to the toxicity of nTiO2 on human-derived mesothelial cells, the crystal form 
rather than the particle size has a greater effect on cellular absorption, and thus causes 
more cellular damage [53]. It is hypothesized that long fiber retention of nanofibers at 
the parietal pleural stomatal openings may lead to chronic inflammation and tumor 
induction eventually, similar to inflammation caused by asbestos exposure (Figure 3) 
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[51]. However, further studies shedding light on nanoparticles uptake and MPM 
induction are to be awaited.  
Long-term effects of ionizing radiation have been made responsible for MPM 
development, however in a much smaller population than in asbestos exposed 
individuals [54]. Especially, individuals exposed to α-particle-emitting agents are at 
higher risk for MPM. Moreover, several studies showed a higher incidence of 
mesothelioma in patients treated with external beam radiotherapy for testicular cancer 
or lymphoma [55, 56].  
Simian virus (SV) 40 was discovered in 1959 as a virus being endemic in rhesus 
monkeys, whose kidneys were used for primary cell cultures for the preparation of 
inactivated poliovirus vaccine (IPV) and live oral poliovirus vaccine. SV40 was shown 
to be oncogenic in rodents, causing mesothelioma, ependymoma, osteosarcoma and 
non-Hodgkin's lymphoma [57]. Formaldehyde was used at the 1950s to inactivate the 
poliovirus, but it did not completely turn down SV40 and thus there have been estimates 
that 30–100 million people in the USA and many more worldwide received potentially 
contaminated vaccines prepared during the years 1955–1963 [58]. In a meta-analysis 
including 528 MPM cases from 15 studies, the risk for the presence of SV40 DNA 
sequences in MPM tumor tissue was very high compared to controls (OR 17, 95% CI 
10–28) [59]. Moreover, recent studies showed that rodents infected with SV40 were 
highly susceptible to asbestos-related carcinogenesis [60]. However, the link between 
SV40 infection and human cancer development is still controversial. 
 
2.1.3 Molecular background of MPM 
Because MPM is rare, genomic studies are limited and typically involve a small number 
of samples [61]. Nevertheless, due to the use of high-throughput analyses and a 
revolution in molecular characterization, the knowledge of cytogenetic and molecular 
changes in MPM has substantially increased in recent years [22]. Recent analyses have 
demonstrated frequent gained chromosomal regions in 5p, 7p, 7q, 8q, and 17q as well as 
frequent deletions of specific sites within chromosome arms 1p, 3p, 6q, 9p, 13q, 15q 
and 22q. Two of these regions are most frequently altered, the tumor suppressors cyclin-
dependent kinase inhibitor 2A (CDKN2A–ARF) at 9p21 and neurofibromin type 2 
(NF2) at 22q12 [62]. These have been known for a long time, but recurrent somatic 
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mutations in BRCA1 (breast cancer 1)-associated protein1 (BAP1) gene were more 
recently identified. BAP1 is a tumor suppressor gene located on 3p21, a chromosome 
region frequently lost in mesothelioma [61]. In contrast to many other solid tumor types, 
MPM has been reported to be rarely mutated in TP53 (Figure 4) [63].  
Only limited data are available on whole genome sequencing of MPM cases. A recent 
study reported several chromosomal copy number variations (CNV) in a single MPM 
tumor sample [64]. In some chromosomes, copy number losses were detected (4, 14, 18, 
19, and 10), others showed gains (5) or a combination of both (1, 8, 9, 11, 15, 16, 17, 
21, and 22). Seventeen tumor-specific genes were identified, some of which are 
considered to be candidates for further investigation regarding future therapeutic 
options. Among genes of interest were mitogen-activated protein kinase kinase 6 gene 
(MAP2K6), dipeptidyl-peptidase 10 (DPP10), pterin-4-alpha-carbinolamine 
dehydratase 2 (PCBD2) and dihydrofolate reductase (DHFR). DHFR is of specific 
interest since it encodes an enzyme being important in the folate metabolism, which 
might be linked to reduced antifolate (ie. pemetrexed) treatment response in some MPM 
patients [65]. 
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Figure 4: Frequency and types of genetic aberrations (mutation, amplification, loss, fusion/rearrangement 
or multiple alteration) among 23 pleural mesothelioma cases [63]. 
In this study, 3 further heterozygous point mutations were identified apart from CNVs. 
These were noted in NK6 homeobox 2 gene (NKX6-2), cadherin 8 gene (CDH8), and 
nuclear factor related to kappa B binding protein gene (NFRKB). 
Genetic alterations can be identified at DNA level (whole genome or exome 
sequencing) or at the mRNA level (i.e. transcriptome sequencing). Several reports are 
already available with these techniques in human MPM. To date, the largest and most 
comprehensive analysis has been reported by Bueno and colleagues [66]. In their study, 
transcriptomes (n=211), whole exomes (n=99) and targeted exomes (n=103) from 216 
MPM patients were analyzed. By whole exome analysis, the following genes were 
found to be significantly mutated: BAP1, NF2, TP53, SET domain containing 2 
(SETD2), DEAD-box helicase 3 (DDX3X), Unc-51 Like Autophagy Activating Kinase 
2 (ULK2), Ryanodine receptor 2 (RYR2), Cilia and Flagella Associated Protein 45 
(CFAP45), SET Domain Bifurcated 1 (SETDB1) and DEAD-Box Helicase 51 
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(DDX51). Furthermore, recurrent gene fusions and splice alterations were identified, 
being frequent inactivation mechanisms for NF2, BAP1 and SETD2. Through 
integrated analyses, alterations in Hippo, mTOR, histone methylation, RNA helicase 
and p53 signaling pathways in human MPM were identified. The authors concluded that 
incorporating genomic analysis for the detection of actionable alterations as part of new 
treatment strategies will help in developing rational individualized therapy in MPM 
patients. 
Based on recent knowledge, it is likely that several mutations need to eventually 
accumulate for MPM development. The long latency period between asbestos exposure 
and MPM formation could support this hypothesis. However, most of the 
aforementioned mutations can be clustered in 4 main intracellular pathways: 
TP53/DNA repair, cell cycle regulation, mitogen-activated protein kinase (MAPK) and 
PI3K/AKT [67]. 
 
 
Figure 5: Affected pathways in MPM. Observed mutations cluster in four main pathways: the tumor 
protein p53 (TP53)/DNA-repair pathway (orange), the cell cycle pathway (blue), the mitogen-activated 
protein kinase (MAPK) pathway (green), and the phophatidylinositol-3 kinase (PI3K)-AKT pathway 
(purple) [67] 
Each of these pathways is known to be important in cell growth, proliferation, and 
survival, processes that are all altered during tumor development [67]. 
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Apart from somatic mutations in MPM, germline BAP1 mutation is the first gene 
reported to predispose for MPM development [68]. BAP1 is a nuclear protein, involved 
in transcriptional regulation, chromatin regulation, and forming part of multiprotein 
complexes that regulate cellular differentiation, gluconeogenesis, cell cycle checkpoints, 
transcription and apoptosis. The BAP1 gene is located on chromosome 3p21, a region 
that shows loss or deletion in 30–60% of mesotheliomas [68]. In families carrying 
BAP1 mutation, there is a dramatically increased incidence of malignant tumors, often 
diagnosed at earlier age compared to the general population [115]. In consequence, a 
“BAP1 cancer syndrome” has been proposed, including mesothelioma, uveal and 
cutaneous melanoma and possibly other malignant tumors [69]. Moreover, germ-line 
BAP1 mutations have been described in families with extraordinarily high incidence of 
mesothelioma [69]. 
 
2.1.4 Histology 
In 2015, the most recent World Health Organization (WHO) classification of tumors of 
the pleura has been published. While the histologic classification of MPM remains the 
same in the 2015 version as it was in the 2004 WHO classification, some new 
observations have been reported [70-72]. MPM derives from pleural stem cells, 
exhibiting both epithelioid and sarcomatoid growing patterns at the same time. 
Depending on which component is predominant, three histological types of MPM can 
be distinguished: epithelioid (50–70 %), sarcomatoid (7–20 %) and a mixed or biphasic 
form (Figure 6) [73, 74]. Within the category of epithelioid MPM, a variety of 
morphologic subtypes are defined, including tubulopapillary, papillary, micro-papillary, 
trabecular, solid, and pleomorphic (Table 1) [71]. Especially the pleomorphic subtype of 
epithelioid MPM has been demonstrated to be associated with significantly poorer 
outcome, similar to that of patients with biphasic or sarcomatoid subtype [75].  
Since there are morphological similarities of MPM to LADC, the histological diagnosis 
of epithelioid MPM can be challenging. However, besides hematoxylin and eosin 
(H&E) staining, additional immunohistochemistry can be a useful in distinguishing 
MPM from secondary malignances (including lung carcinomas) spreading to the pleura. 
Specificity and sensitivity considerations support the use of calretinin, cytokeratins 5/6, 
WT-1, and podoplanin (D2-40) as positive mesothelial markers, and carcinoembryonic 
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antigen (CEA), B72.3 (recognizing tumor-associated glyocoprotein 72), Bg8 (blood 
group 8, detecting the Lewis Y antigen, type 2 chain), BerEP4 (differentiating glandular 
epithelium from mesothelium) and MOC-31 as positive carcinoma markers [71]. 
 
Figure 6: Examples of epithelioid a), biphasic (b) and sarcomatoid (c) MPM [73]. 
Table 1: Histological specification of malignant pleural mesothelioma [70, 72] 
Epithelioid Sarcomatoid Biphasic mixed 
– Tubulopapillary 
– Acinar 
– Glandular 
– Adenomatoid 
– Solid epithelioid patterns 
– Small cell 
– Oat cell 
– Pleomorphic 
Differential diagnosis: 
metastatic carcinomas and 
other epithelioid tumors 
Mimic malignant 
mesenchymal tumors: 
leiomyosarcoma synovial 
sarcoma 
Desmoplastic mesothelioma 
bland tumor cells 
Differential diagnosis: 
sarcomatoid carcinoma and 
other sarcomas 
Combination of all 
epithelioid and 
sarcomatoid features 
Differential diagnosis: 
Synovial sarcoma, other 
mixed or biphasic tumors 
 
Sarcomatoid MPM consists of irregularly arranged elongated spindle cells, which show 
no uniformity in shape. The biphasic subtype shows a mixture of both, epithelioid and 
sarcomatoid elements. 
The pathological diagnosis and differential diagnosis of MPM can be very challenging. 
In a French study, the initial diagnosis of MPM was revised as false positive in 13 % of 
cases [76]. This can be explained in part by the fact that MPM can present in very 
heterogeneous forms on the one hand and must be distinguished from benign processes 
and other tumors. Such a differential diagnosis can be particularly difficult since 
mesothelioma-like features can also be found in some lymphomas, thymomas, and 
carcinomas, etc. However, Brcic and colleagues found a substantial interobserver 
reproducibility among two observers in the histological subtyping of MPM [74].  
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In small tissue biopsies, early invasive MPM is particularly difficult to be diagnosed, 
often disguised by cutting artefacts or the malorientation of sections, but may be 
suspected if there is nodular mesothelial cell proliferation. If definitive invasion cannot 
be identified, the diagnosis of “atypical mesothelial proliferation” is appropriate, and 
further sampling may be indicated. Distinguishing MPM from inflammatory pleural 
disease requires a full-thickness biopsy sample, with correct orientation of histological 
sections, perpendicular to the pleural surface [77, 78]. 
Moreover, some specific morphologic criteria are recognized in order to distinguish 
MPM from reactive mesothelial hyperplasia and organizing pleuritis and these are 
depicted in Table 2. However, the application of these criteria might be challenging due 
to size of the specimens, sampling problems, entrapment of mesothelial cells and 
superficial or tangential cuts [71, 79, 80]. 
 
Table 2: Tissue features of reactive atypical mesothelial hyperplasia versus epithelioid MPM. Adopted 
from [71] 
 
 
2.1.5 Screening, clinical diagnosis, prognosis and staging of MPM 
In current international guidelines (ie. European Society of Thoracic Surgeons/European 
Respiratory Society (ESTS/ERS) guidelines), no general screening methods in order to 
detect asymptomatic MPM are recommended. This is based on the low sensitivity of 
even advanced imaging techniques such as low-dose computed tomography (CT) in 
screening of asbestos workers [81]. Circulating biomarkers such as fibulin-3, 
osteopontin, mesothelin-related peptides and soluble mesothelin-related peptide 
(SMRP) have been extensively investigated in MPM and asbestos exposed individuals 
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[82-84]. However, none of them are yet to be considered as a reliable screening tool [81, 
85, 86].  
Specific clinical symptoms of MPM are comprised of dyspnea, cough and chest pain on 
initial examination. Dyspnea is often caused by pleural effusion and later by extensive 
restriction due to pleural and pulmonary tumor masses in the thoracic cavity. Chest pain 
might be diffuse, sometimes radiating into the shoulders, arms or abdomen. Tumorous 
invasion of the brachial plexus and the intercostal or paravertebral nerves can 
additionally cause neuropathic pain. Weight loss is a symptom of more advanced 
disease [73]. Since MPM development is associated with previous asbestos exposure (as 
described above), it is recommended to obtain a detailed occupational history [86]. 
Typically, MPM occurs as an initially unilateral disease. During disease progression, 
the tumor can, however, spread to the contralateral pleural cavity or into the peritoneum. 
Compared with lung cancer, distant metastases in the extrathoracic lymph nodes or in 
other parenchymal organs are usually rare, although they do occur at more advanced 
stages [87].  
In patients with suspected MPM and recurrent pleural effusions and/or pleural 
thickening, the recommended initial evaluation includes contrast-enhanced computed 
tomography (CT) scan of the chest, thoracentesis for cytological assessment of the 
effusion, pleural biopsy and general laboratory blood tests [73, 81, 85, 86]. Plain chest 
x-ray lacks sufficient sensitivity for routine diagnosis and staging as significant pleural 
effusions can mask pleural lesions. 
 
 
Figure 7: Computer tomography of a patient with MPM showing circular involvement of the visceral and 
parietal pleura, pericardium and mediastinum. Pulmonary window (left) and mediastinal window (right). 
Adopted from [73] 
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By radiological approaches, it can be difficult to distinguish between malignant and 
benign pleural disease and also to distinguish MPM from other malignant tumors 
spreading to the pleura such as metastatic carcinomas, sarcomas and thymomas [78]. 
A thoracoscopy is recommended to obtain adequate biopsies for histological 
verification, to optimally stage and to allow pleural fluid evacuation (with or without 
pleurodesis). This can usually be performed as a pleuroscopy or as video-assisted 
thoracic surgery (VATS). Fine-needle aspiration (FNA) is not routinely recommended 
for diagnosing MPM as its diagnostic yield is inferior compared to thoracoscopy [88]. 
MPM can be difficult to pathologically identify and it is therefore recommended to 
obtain biopsies from tissue of both abnormal and normal appearance. In case a VATS is 
not feasible or contra-indicated, ultrasound-guided true-cut biopsies are a good 
alternative [86]. When a biopsy is not possible, appropriate clinical and radiological 
features may assist in suggesting a diagnosis of MPM. In very rare cases, a surgical 
open biopsy might be necessary for definitive tissue diagnosis [8]. Micro-anatomical 
assessment of tissue biopsy samples permits to measure the level of host tissue invasion. 
Immunohistochemistry (IHC) is pivotal in confirming the mesothelial origin of MPM 
cells, but cannot confirm their biological potential. A larger tissue biopsy and more 
targeted sampling approach (radiological or surgical (VATS or open procedure)) might 
result in a more reliable and definitive diagnosis. Thus, in the vast majority of cases, 
adequate tissue biopsies and the use of appropriate IHC for definitive, primary diagnosis 
of MPM are necessary. Consequently, definitive histopathological diagnosis of MPM 
by using frozen sections is not recommended [86]. Cytological features in effusions 
may permit a diagnosis of malignancy but reported sensitivities and specificities vary 
widely [77, 89]. In a high number of cases, MPM lacks significant cytological atypia 
and it is impossible to distinguish between benign, reactive mesothelial proliferations 
and MPM. Cytology sample cells may show variable atypia (usually low grade) and 
exhibit a mesothelial immune phenotype, but malignancy cannot be confirmed in most 
of the cases.  
Because the precise diagnosis of MPM requires histopathological confirmation, 
thoracoscopy via VATS in operable patients remains the standard procedure for 
obtaining tissue and performing macroscopic staging at the same time (Figure 8) [73, 
81]. 
 - 26 - 
 
 
Figure 8: VATS view of forceps biopsy taken from tumor nodules located on the parietal pleura of a 
patient with MPM. Note the black streaks of anthracotic pigment visible between lobules of the lung 
beneath the visceral pleura (a). Macroscopic view of the chest cavity after talc pleurodesis (d). Adopted 
from [73] 
Thoracoscopy can be performed under local anesthesia or via surgical approach by 
VATS in general anesthesia. The VATS procedure allows the combination of a 
diagnostic procedure with an initial palliative/therapeutic step of talc pleurodesis. 
Multiple and deep tissue biopsies obtained by a thoracoscopic procedure are strongly 
recommended by the Guidelines of the ERS and ESTS, except in the case of pre-
operative contraindication or pleural symphysis [81]. Thoracoscopy should be preferred 
for diagnostic investigation as it allows complete visual examination of the pleura, 
taking multiple, deep and large biopsies (preferably including fat and/or muscle to 
assess tumor invasion) and providing a diagnosis in >90% of cases [81].  
In cases being considered inoperable, the aforementioned diagnostic procedures should 
be performed obligatory before starting local or systemic treatment. In order to stage 
and assess patients diagnosed with MPM whether they are candidates for surgery, the 
National Comprehensive Cancer Network (NCCN) guidelines as well as the guidelines 
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of the Austrian Mesothelioma Interest Group (AMIG) suggest to perform contrast 
enhanced CT of the chest and the abdomen and combined fluorodeoxyglucose positron 
emission tomography (FDG-PET) CT to rule out distant metastasis and involvement of 
the abdomen and the mediastinal lymph nodes (Figure 9) [85]. VATS or laparoscopy 
can be considered if contralateral pleural or peritoneal spread is suspected. If indicated, 
integrated FDG-PET/CT should ideally be performed before pleurodesis, since talc 
causes pleural inflammation, which can result in false positive findings by affected FDG 
avidity [90]. 
 
 
Figure 9: FDG PET-CT images: MPM of the right pleural cavity. Various slides of CT/PET fusion 
imaging showing pleural tumor apical right (top left), involving the visceral and parietal pleura of the 
costodiaphragmatic area (bottom left and right) and pericardium (top right). Adopted from [73] 
In order to rule out involvement of mediastinal lymph nodes, histological confirmation 
has to be made either by endobronchial/endo-esophageal ultrasonography and 
transbronchial needle aspiration (EBUS/EUS-TBNA) or mediastinoscopy or VATS 
according to the lymph node station involvement and the involved side [91, 92]. 
A possible algorithm for diagnosis and staging as proposed by the NCCN is depicted in 
Figure 10. 
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Figure 10: Initial diagnostic and staging procedures for patients with MPM as proposed by the NCCN 
[85]. 
Staging procedures are standard in all malignant tumors including MPM. An 
appropriate staging system describes the anatomical extent of the tumor, correlates with 
prognosis and facilitates treatment decisions. In case of MPM, different staging systems 
have evolved during the past 30 years, most initially developed from small single-center 
experiences and predominantly retrospective surgical cases [93]. The first staging 
system by Butchart consisted of four stages and was based on observations from 29 
patients only [94]. Another staging system as proposed by the International 
Mesothelioma Interest Group (IMIG) and the International Association for the Study of 
Lung Cancer (IASLC) was developed in 1995 [95]. Although the IMIG staging system 
could predict prognosis, it failed to be an independent prognostic factor when analyzed 
in the clinical setting using multivariate analysis [96]. The most recent staging system is 
based on a large international database analysis, set up by the IASLC and was recently 
published in 2016 [47, 97, 98].  
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Figure 11: TNM stage groupings of the revised TNM-8 versus the previous TNM-7 staging system in 
MPM. Adopted from [97] 
The most important changes compared to the previous IMIG/IASLC staging system 
include: the incorporation of both clinical and pathological T1a and T1b into a T1 
category and both clinical and pN1 and pN2 categories into a single N category 
(comprising ipsilateral, intrathoracic nodal metastases (N1)). Nodes that have been 
previously categorized as N3 are reclassified as N2 now (Table 3). Furthermore, 
measurement of pleural thickness on CT scans has been proposed for further studies, as 
tumor thickness and nodular or rind-like morphology were significantly associated with 
survival. These recently proposed revisions for the TNM-8 stage descriptors and 
groupings should provide a better estimation of outcomes. In the future, additional data 
collected from both surgically and non-surgically managed patients will also help to 
refine these stage groupings (Figure 11) [97]. 
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Table 3: Definitions for T, N and M descriptors in the recently revised TNM-8 staging system for MPM. 
Adopted from [97] 
 
 
Several clinical prognostic factors for MPM have been reported. These are similar to 
those described in other solid tumor types. The prognosis for MPM highly depends on 
the tumor stage and histological subtype and, moreover, on the patient’s age and 
gender[99]. Patients with epithelioid MPM has a better OS than those with non-
epithelioid tumors (median OS: 19 months vs. 13 months (biphasic) and 8 months 
(sarcomatoid)) [100]. In addition, performance status (PS) has shown to be an 
independent prognostic factor for OS [8]. Low hemoglobin levels, high platelet levels 
and high serum lactate dehydrogenase (LDH) are prognostically unfavorable 
characteristics. Numerous new laboratory markers with the purpose of facilitating 
decision making are have been evaluated, but no validated data on their prognostic 
value are available yet [101]. Additionally, our group has previously shown that high 
circulating c-reactive protein (CRP) and fibrinogen are generally associated with poor 
prognosis, independently from stage and histological subtype [102, 103]. 
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In general, MPM is a devastating disease and despite many efforts regarding early 
detection and treatment, outcome remains poor. Even at early stages, minimal tumor 
burden and lack of distant metastases, median OS ranges from 18 to 23 months, with an 
expected 5-year survival rate of 15% only [97].   
 
 
Figure 12: Overall survival according to the TNM-8 staging system for MPM. Adopted from [97] 
In more advanced stages, palliative treatment approaches might be necessary and most 
of the patients die from tumor cachexia, body consumption and respiratory problems 
caused by secondary pneumonia and respiratory insufficiency with hypoxia and 
asphyxia. 
 
2.1.6 Therapeutic approaches 
Current treatment guidelines recommend that patients with MPM should be managed by 
a multidisciplinary team with experience in treating MPM. Treatment options in general 
include chemotherapy (CHT), radiotherapy (RT) and surgery. Selected cases with 
favorable prognostic parameters (i.e. clinical stage I, medically operable, good PS, 
epithelioid subtype) might be candidates for combined multimodality therapy [104, 
105]. Definitive RT alone is not recommended for unresectable MPM, however, CHT 
alone is approved in this setting [85, 106]. Appropriate patients should undergo 
evaluation by medical oncologists, radiation oncologists, thoracic surgeons, diagnostic 
imaging specialists and pulmonologists in order to assess if they are amenable for 
multimodality treatment. Best supportive care is recommended for patients with PS 3 to 
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4. Observation may be considered for patients with PS 0 to 2 who are asymptomatic 
with minimal disease burden if CHT is planned when progression occurs [85]. 
 
2.1.6.1 Systemic therapy 
In general, CHT alone is recommended for patients with PS 0 to 2, clinical stage IV 
disease, sarcomatoid histology (due to the poor prognosis) or who are not candidates for 
surgery [85]. 
Prior to the early 2000s a nihilistic attitude persisted among clinical oncologists towards 
anti-MPM therapy because of the lack of response to standard therapies. Nevertheless, 
although the role of aggressive surgery remains controversial and no chemo- or targeted 
therapy has proved fully effective against MPM, robust evidence has emerged to 
support the use of chemotherapy and angiogenesis inhibition during the past decades 
[42].  
In a meta-analysis including all phase II studies published between 1965 and 2001, 
cisplatin was found to be the most effective single agent and thus it became the 
mainstay for combinational therapeutic interventions in MPM [107]. Accordingly, after 
encouraging data of phase I and II pemetrexed (a multitargeted antifolate that inhibits 
thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl 
transferase) studies, a single-blinded phase III trial (Evaluation of Mesothelioma in a 
Phase III Trial of pemetrexed with Cisplatin, EMPHACIS) recruited 448 chemonaive 
patients with MPM randomly assigned to receive cisplatin at 75 mg/m2 plus either 
pemetrexed at 500 mg/m2 or placebo every 3 weeks [108]. The median OS in the 
combination arm was 12.1 months, compared to that of 9.3 months in cisplatin-alone 
patients. Based on this study, combination chemotherapy with pemetrexed and cisplatin 
(with folic acid and vitamin B12 supplementation) became the current standard of care 
for first-line systemic therapy in patients with unresectable MPM and good PS. 
Although cisplatin monotherapy was never compared to placebo in a randomized trial, 
these results enforced the recommendation for combination chemotherapy. So far, all 
current major international guidelines endorse a combination of platinum-based CHT 
with modern antifolates (pemetrexed or raltitrexed) as the gold standard treatment in 
MPM [81, 85, 86, 109]. Still, it has to be mentioned that these recommendations are 
based on two randomized trials published in more than a decade ago [108, 110]. 
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Accordingly, until 2015, no other combination therapy was able to significantly 
improve OS and progression free survival (PFS) compared to the cisplatin/pemetrexed 
doublet [86]. However, previous studies have demonstrated that vascular endothelial 
growth factor (VEGF) signaling plays a crucial part in mesothelioma cell 
physiopathology [111, 112]. The phase II/III randomized Mesothelioma Avastin 
Cisplatin Pemetrexed Study (MAPS) was initiated to assess the effect on survival of the 
VEGF inhibiting monoclonal antibody bevacizumab when added to the present standard 
of care, cisplatin/pemetrexed, as first-line treatment of advanced MPM[113]. Survival 
was improved in those who received cisplatin/pemetrexed/bevacizumab (18.8 months, 
versus 16.1 months in patients receiving CHT alone (hazard ratio 0.77 [95% CI 0.62–
0.95]). Although statistically significant, the overall improvement in OS (2.7 months) 
was still quite modest. Grade 3-4 adverse events were more common in the 
bevacizumab group (158 [71%] of 222 patients) (139 [62%] of 224 patients), and more 
patients stopped first-line treatment because of toxic effects in the bevacizumab group 
(53 [24.3%] of 218 patients) (13 [6.0%] of 217; difference 18.3% [11.7–24.9]). 
However, these side effects were considered to be tolerable and thus those patients with 
MPM who are not candidates for clinical trials or who do not have access to such 
opportunities, but who do not have contraindications to bevacizumab, should be offered 
three-drug combination treatment as a new standard of care [85]. 
Some other recent phase II and III trials have assessed the safety and efficacy of 
different systemic combination treatments. A combination of carboplatin and 
pemetrexed was investigated in 3 large phase II trials with median OS ranging from 
12.7 to 14 months [114-116]. A comparison of 1704 patients with inoperable MPM 
treated with ether cisplatin/pemetrexed or carboplatin/pemetrexed found that outcomes 
were similar and concluded that the carboplatin/pemetrexed regimen might be the better 
choice for patients with poor PS and/or comorbidities [117]. Cisplatin/gemcitabine was 
assessed in phase II studies and was found to be a valid treatment option for patients not 
eligible for pemetrexed treatment [118]. Additional acceptable fist-line single agent 
regimens include pemetrexed or vinorelbine monotherapy (Table 4) [119, 120]. 
Maintenance therapy after successful first-line systemic treatment might be effective for 
symptom control and maintaining quality of life [86]. However, the benefit of 
maintenance treatment in MPM is yet to be evaluated and several studies are ongoing. 
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For example, a recent phase III randomized trial has failed to show a benefit of adding 
maintenance thalidomide to pemetrexed-based CHT [121]. 
Second-line CHT options include pemetrexed (if not administered as first-line), 
vinorelbine and gemcitabine [122-124]. In patients with good response to first-line 
pemetrexed, rechallenging pemetrexed might be effective [125]. Limited data are 
available to guide second-line systemic therapy; however, several agents are 
investigated in clinical trials [126]. Preliminary data suggest that immune checkpoint 
inhibitors (nivolumab, pembrolizumab, tremelimumab, ipilimumab) might be effective 
in the second-line setting and thus currently phase II and III trials are ongoing [127, 
128]. In a recent randomized phase IIb trial, the CTLA-4 inhibitor tremelimumab did 
not significantly prolong OS compared with placebo in patients with previously treated 
malignant mesothelioma [129]. However, preliminary phase II results from a 
prospective randomized trial evaluating the safety and efficacy of cisplatin/pemetrexed 
with the triple angiokinase-inhibitor (TKI) nintedanib revealed a trend for better OS and 
significantly better PFS for the experimental arm. The confirmatory phase III results are 
to be awaited [130]. 
 
Table 4: Principles of systemic therapy in MPM according to the most recent NCCN guidelines (2.2017). 
Adopted from [85] 
First-line Later lines 
Cisplatin, Pemetrexed Pemetrexed 
Cisplatin, Pemetrexed, Bevacizumab Vinorelbine 
Carboplatin, Pemetrexed Gemcitabine 
Cisplatin, Gemcitabine Nivolumab, Ipilimumab 
Pemetrexed Pembrolizumab 
Vinorelbine 
 
 
Interleukins and interferons were tested in studies, as well as the application of targeted 
therapies with monoclonal antibodies. None of the following substances showed any 
survival benefit in several studies: gefitinib, erlotinib, or imatinib [131-134]. 
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2.1.6.2 Surgery 
2.1.6.2.1 Radical surgical approaches 
Macroscopic complete resection (MCR) is goal of every surgical procedure with 
curative intent [135]. Currently, multimodality treatment including radical surgery as by 
extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) are the most 
commonly used surgical techniques for treating MPM with curative intention. However, 
only a number of mainly retrospective institutional reports using different multimodality 
regimens and different surgical techniques is available in the current literature, due to 
the difficulty of prospective randomized trials in this setting. Hence, the question 
whether P/D or EPP is the more appropriate technique to obtain improved OS in 
relation to the associated posttreatment quality of life is difficult to address. After the 
IMIG 2012 meeting and much discussion on the role of surgery and the value of MCR 
in MPM, the agreement is now that (I) surgical macroscopic complete resection and 
control of micrometastatic disease play a vital role in the multimodality therapy of 
MPM, as in case of other solid tumor types. (II) Surgical cytoreduction is indicated 
when MCR is deemed achievable and (III) the type of surgery (EPP or P/D) depends on 
clinical factors and on individual surgical judgment and expertise [135]. 
However, since MPM is a very heterogeneous disease with variability of clinical 
symptoms, stage, histology, tumor burden and biological behavior, a multidisciplinary 
discussion of each patient considering age, PS and individual prognosis is mandatory. 
 
2.1.6.2.2 Pleurectomy/Decortication 
As the technique of P/D includes a variety of surgical procedures with different clinical 
indications, the IASLC and IMIG have recently proposed a common nomenclature for 
these different techniques [136]. Partial pleurectomy was defined as a cytoreductive 
procedure with partial removal of the visceral and/or parietal tumor gross, without 
removing the lung or the intention for MCR. P/D was defined as complete resection of 
the parietal and visceral pleurae, and extended P/D as a technique with additional 
resection and reconstruction of the pericardium and diaphragm (Figure 13). In a recent 
systematic review investigating previous results of P/D, mortality and morbidity ranged 
from 0% to 11% and 13% to 43%, respectively. Median OS ranged from 7.1 to 31.7 
months and disease-free survival (DFS) from 6 to 16 months [137]. A detailed analysis 
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suggested extended P/D to be associated with a higher number of perioperative 
morbidity whilst favoring the more aggressive approach for improved oncological 
outcome.  
 
 
Figure 13: Surgical technique of extended pleurectomy/decortication for MPM. Adopted from [138] 
2.1.6.2.3 Extrapleural Pneumonectomy 
Extrapleural pneumonectomy (EPP) is a widely standardized surgical technique with 
en-bloc resection of the lung together with the parietal and visceral pleurae, the 
pericardium and diaphragm (Figure 15) [139]. The role of EPP has been recently under 
discussion after the publication of the Mesothelioma and Radical Surgery (MARS I) 
trial which aimed to assess the outcomes of patients after EPP or no EPP in the context 
of trimodal therapy within a prospective randomized trial [140]. Median OS was 14.4 
months (5.3-18.7) for the EPP group and 19.5 months (13.4 to time not reached) for the 
no EPP group. EPP was associated with an unacceptably high perioperative mortality of 
15.8% and morbidity of 68.8%. However, only 16 of the randomized patients have 
undergone EPP. The authors of the study concluded that radical surgery by EPP within 
a multimodality approach offers no benefit in OS and possibly harms patients. 
However, the MARS I trial was designed to assess the feasibility of randomizing 
patients with MPM for surgery and not to evaluate morbidity or benefit in OS of EPP. 
In order to sufficiently address this question an actual number of 670 patients to identify 
a significant survival benefit would have been needed [135]. A recent systematic review 
including 58 studies reported a median OS after EPP of 9.4 to 27.5 months, and 1-, 2-, 
and 5-year survival rates ranging from 36 to 83%, 5 to 59% and 0 to 24%, respectively. 
Overall perioperative mortality ranged from 0 to 11.8%, and the perioperative morbidity 
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from 22 to 82% [141]. A recent retrospective evaluation of our own group together with 
colleagues from Toronto and Zurich including 251 patients completing EPP after platin-
based CHT reported a 30-day mortality of 5% and perioperative complication rate of 
30% [105]. However, according to the recent ERS/ESTS guidelines, EPP should only 
be performed at high volume centers within the context of a clinical study and a 
multimodality regimen [81]. Moreover, the current NCCN guidelines suggest to 
perform EPP in early stage patients only [85]. 
 
 
Figure 14: Surgical technique of extrapleural pneumonectomy for MPM. Adopted from [138] 
 
   
Figure 15: Resection specimens after extrapleural pneumonectomy for MPM at the Division of Thoracic 
Surgery, Medical University of Vienna 
The question whether to perform P/D or EPP in which clinical situation is difficult to 
address. Initial data from the IASLC Staging Committee Statistical Center including 
1494 surgically-treated patients reported that stage I tumors resected by EPP were 
associated with a median OS of 40 months whereas those managed by P/D had a 
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median OS of 23 months. No differences in survival between EPP and P/D were 
identified in patients with higher-stage disease [100]. To date, the largest cohort of 
patients treated with P/D or EPP was published by Flores et al in 2008. Of 663 
consecutive cases, the operative mortality was 7% for EPP (n = 27/385) and 4% for P/D 
(n = 13/278) [142]. OS was reported to be superior after P/D, however patients selected 
for EPP had more local advanced disease and P/D was applied in earlier stages. Another 
recently published meta-analysis compared the perioperative and long-term outcomes of 
EPP and extended P/D for selected surgical candidates [143]. A comparison between 
EPP and P/D revealed a significantly lower perioperative mortality and morbidity for 
patients who underwent extended P/D compared to EPP. Median OS ranged between 
13-29 months for extended P/D and 12-22 months for EPP, with a trend favoring 
extended P/D. The authors concluded that selected patients who underwent extended 
P/D had lower perioperative morbidity and mortality with similar, if not superior, long-
term survival compared to EPP, in the context of multi-modality therapy. However, it 
must be taken into account that in most of the included studies, P/D was usually chosen 
for earlier and EPP for more advanced stages. 
 
2.1.6.2.4 Patient selection for surgery 
Taken all this information together, patients undergoing surgery for MPM must be 
carefully selected to outweigh the potential risks with the respective procedures. Several 
studies have been published assessing clinical prognostic factors and biomarkers for 
estimating prognosis and proper patient selection. For example, non-epithelioid 
histology and nodal involvement have consistently been demonstrated to be associated 
with worse prognosis after EPP [144]. Furthermore, several blood biomarkers and 
combinations of several clinical factors as prognostic scores have been investigated to 
identify patients who are more likely to benefit from surgical treatment. Among these, 
pre-treatment CRP predicted benefit in OS from multimodality therapy including 
curative intent surgery [102]. Multivariate analysis confirmed that patients with low 
CRP levels have significantly improved OS compared to those with elevated levels 
independently from other relevant clinical factors. Moreover, circulating biomarkers 
such as fibrinogen and albumin were reported to influence prognosis and could be 
implemented into therapeutic algorithms [103, 145]. Our study group has recently 
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combined our experience with the colleagues from Zurich, Switzerland in order to 
assess the prognostic value of a new multimodality score including the following 
factors: tumor volume, histology, CRP and response to CHT. This prognostic score was 
found to be useful in allocating patients to surgery after CHT in the two independent 
cohorts [146]. Moreover, patient data from 10 European Organization for Research and 
Treatment of Cancer (EORTC) trials of chemotherapy in MPM were pooled and PFS at 
18 weeks strongly correlated with OS and discriminated those with improved OS from 
the patients with poorer prognosis [147]. 
Finally, not much data is currently available on quality of life (QoL) after surgical 
treatment of MPM. A recent study has included QoL data in their institutional report 
and found a superiority of P/D versus EPP in QoL after 6 and 12 months [148]. In line 
with this, the MARS trial found that QoL scores were higher in the non-EPP group, 
however, no significant differences between groups were observed in QoL analyses 
[140]. 
 
2.1.6.2.5 Multimodality treatment 
Several studies found that surgery alone offers poor prognosis and thus multimodality 
approaches including CHT and/or RT have been suggested to improve outcome. 
However, to date, there are no randomized trials available addressing the question if 
chemo-, radio- or combined chemo/radiotherapy might be the preferred induction 
treatment before surgery. Before EPP, many high-volume institutions reported on 
favorable experiences with induction CHT followed by surgery and hemithoracic 
intensity modulated radiotherapy (IMRT) [142, 149]. The obvious advantage of 
induction CHT is a possible reduction of tumor volume and the consequent 
downstaging. The effects of induction CHT and EPP have recently been studied in a 
prospective multicenter phase II trial including 61 patients. Forty-five patients (74%) 
underwent EPP and in 37 patients (61%) the resection was complete. Postoperative RT 
was administered in 36 patients. Median OS of all patients was 19.8 months. In the 45 
patients with EPP, median OS was 23 months [150]. A new multimodality protocol was 
recently suggested by the Toronto group and is currently under investigation in the 
“Surgery for Mesothelioma After Radiation Therapy (SMART)” trial. A short 
accelerated course of high-dose hemithoracic IMRT is administered followed by EPP 
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[151]. A total of 62 patients were included so far. The median OS of all patients was 36 
months (51 months in the subgroup of patients with epithelioid MPM). Moreover, 
complication rates of this protocol were found to be acceptable. These results suggest 
that this protocol is feasible without elevated perioperative morbidity and mortality and, 
moreover, that it provides encouraging long-term outcome [152]. However, further 
prospective trials are needed to investigate the value of different multimodality 
strategies in the treatment of MPM. 
Intracavitary treatment 
Because of MPM's locally invasive behavior, it is difficult to achieve R0 resection in 
MPM patients and thus local recurrence is a frequent problem after MCR (reported in 
up to 60% of cases [142]). Recently, new treatment strategies have evolved such as 
intracavitary chemo- or photodynamic therapy to secure resection margins at the end of 
the operation and consequently lower the risk of local recurrence. 
Intracavitary photodynamic therapy (PDT) combines a nontoxic photosensitizing agent 
with visible light. PDT is used intraoperatively after P/D or EPP [153]. A study 
combining PDT with radical pleurectomy in patients with stage III/IV disease reported a 
median OS of 31.7 months for all patients and 41.2 months for patients with epithelial 
histology [154]. The authors concluded that this combination is effective and safe and 
thus warrants further prospective investigation. 
Hyperthermic intraoperative chemotherapy (HIOC) delivers a high local dose CHT to 
the resected surface with decreased toxicity compared to systemic therapy [155, 156]. 
The feasibility and effects of HIOC have recently been investigated in several phase II 
trials and encouraging PFS and OS have been reported in patients with epithelioid MPM 
and low risk factors [157-159]. One particular study reported encouraging results after 
open partial pleurectomy and HIOC with 35.6 months median OS in stage I patients 
[160]. 
Other intracavitary treatment concepts of binding cytotoxic (or other agents) to a fibrin 
carrier are currently evaluated in prospective trials. The concept of localized 
intracavitary fibrin bound cisplatin-based chemotherapy after MCR is evaluated in a 
phase IIa trial conducted in Zurich to assess safety and toxicity of this protocol 
(NCT01644994 Influence Meso) [161].   
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2.1.6.2.6 Palliative surgery 
In a high number of patients, MPM is diagnosed at advanced stage and symptom control 
plays an important role in achieving palliation [162]. Typical symptoms include 
dyspnea due to pleural effusion or lung encasement by tumor gross, weight loss, cough 
and chest pain in case of thoracic wall invasion. In case of effusion, drainage for 
symptom control is recommended followed by pleurodesis at first relapse [81]. Sterile 
talc powder is the preferred sclerosing agent and can be installed using a chest tube or 
after VATS biopsy if the lung expands completely [81, 162]. In case of an entrapped 
lung, indwelling pleural catheters may be the most practical way to manage recurrent 
pleural effusions [163, 164]. Recently, the MesoVATS trial has randomized MPM 
patients to undergo VATS pleurectomy vs. talc pleurodesis via indwelling intercostal 
chest drain or via thoracoscopy [165]. VATS partial pleurectomy (VATS-PP) did not 
significantly improve OS and talc pleurodesis was considered to be preferable due to 
fewer complications and shorter hospital stay. However, VATS-PP was significantly 
associated with improved control of pleural effusions and improved QoL at 12 months. 
 
2.1.6.3 Radiotherapy 
In patients with MPM, RT can be used as part of multimodality treatment protocol. 
However, RT alone is not recommended due to its poor efficacy. RT as a monotherapy 
may be used in a palliative attempt in patients not eligible for CHT for relief of chest 
pain, bronchial or esophageal obstruction or other symptomatic sites associated with 
metastases such as brain or bone [166, 167]. The dose should be based on the purpose 
of the treatment (Table 5).  
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Table 5: Principles of radiotherapy in MPM. Recommended doses and schedules based on the treatment 
purpose. Adopted from [85] 
 
 
Neoadjuvant RT can be performed prior to EPP as described in chapter 0. The concept 
of SMART aims to increase resectability and to decrease local recurrence rate after 
MCR [151, 152]. In this setting, RT is delivered hypofractionated, applying a higher 
dose of 5 Gray (Gy) on 5 consecutive days with an integrated boost of 6 Gy to target 
areas of high tumor volumes. The target volume includes the whole lung including the 
pleural surface. IMRT is used to reduce high doses at organs at risk such as heart, 
esophagus, liver or spinal cord. Since a toxic dose is delivered to lung within this 
protocol, the EPP has to be performed within 1 week after last RT in order to avoid 
pneumonitis. 
Adjuvant IMRT was regarded as an integral part of the classical trimodality treatment 
including CHT, EPP and adjuvant RT [86]. The dose of 50–54 Gy should be applied 
with a once daily fraction of 1.8–2.0 Gy (Table 5). The RT is usually administered 
between 4-12 weeks after surgery, depending on the recovery of the patient. The 
treatment plans should be reviewed with a thoracic surgeon to ensure coverage of all 
targets at risk [85]. The safety and efficacy of this approach has been investigated in 
larger retrospective series and one prospective phase II study [139, 168, 169]. A recent 
randomized multicenter phase II trial has investigated the role of adjuvant IMRT after 
CHT and EPP [170]. In total, 151 patients were randomized to receive CHT and EPP 
followed by adjuvant IMRT or follow-up. Median locoregional relapse-free survival 
from surgery was 7.6 months in the group without RT and 9.4 months in the RT group 
(not being statistically significant). Accordingly, the authors concluded that these results 
do not support the routine use of adjuvant IMRT in this setting. 
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Figure 16: Postoperative situs after EPP of the right lung and pleura. IMRT dose plan. Coronal, sagittal, 
and axial image of the isodose plan. Steep dose fall to the remaining left lung, liver and kidney. Adopted 
from [109] 
2.1.7 Prognostic tissue biomarkers in MPM 
In the past decades, several characteristics of patients with MPM have been reported to 
be associated with prognosis. These factors include clinicopathological characteristics 
such as age, gender, performance status, asbestos exposure, stage and histological 
subtype [171]. In recent years, extensive research aimed to identify new therapeutic 
targets, predictive biomarkers and prognostic factors in this disease. MPM cells have a 
number of well investigated chromosomal and genetic aberrations and may express a 
large array of cancer associated molecules and proteins which are linked to local 
invasion and disease progression[172]. These molecules include circulating and tissue 
biomarkers related to multiple cellular pathways affecting cell survival, proliferation, 
apoptosis, angiogenesis, interaction with immune response and DNA repair mechanisms 
[172].  
 - 44 - 
 
Certain cell surface molecules have been shown to mediate proliferation through 
binding of their circulating ligands and interact with endothelial and immune response 
cells in many human solid tumor types [173]. Epidermal growth factor receptor 
(EGFR), a well-studied receptor-tyrosine kinase (RTK), was investigated in 168 MPM 
samples using IHC. EGFR expression was significantly associated with epithelioid 
histology and correlated with OS in univariate analysis [174]. C-MET, another RTK 
known to be frequently overexpressed in human cancers, was associated with OS in 
IHC studies analyzing its staining intensity and intracellular localization (i.e. membrane 
or cytoplasm). Also, c-MET localization to the cell membrane was an independent 
prognostic factor in multivariate analysis [175]. High tissue expression of Axl, a RTK 
of the TAM subfamily, mediating cell survival and epithelial-to-mesenchymal transition 
(EMT) by binding to its ligand growth arrest signal-6 (Gas-6), was associated with 
favorable prognosis and epithelioid histology in 63 MPM patients [176]. Syndecan-1, a 
member of proteoglycans which mediate adhesion, migration, cytoskeletal organization, 
angiogenesis, differentiation and proliferation, was overexpressed in epithelioid 
compared to sarcomatoid MPM, and its presence was associated with longer OS in 
analysis of 52 cases [177]. Neurotensin (NTS), a regulator of intestinal motility, 
secretion, smooth muscle activity and epithelial proliferation in physiological 
conditions, and its receptor NTSR1, have been investigated in 52 MPM samples. NTS 
expression conferred with inferior survival in univariate and multivariate analysis, with 
no such tendency for NTSR1 [178]. Expression of CD9, a member of the tetraspanin 
membrane glycoproteins, exhibiting tumor-promoting or -suppressing effects and 
involved in cell adhesion, invasion, metastasis and angiogenesis, was associated with 
younger age, epithelioid subtype and better differentiation as well as longer OS in 
univariate and multivariate analysis in 112 MPM patients [179]. CD26, involved in 
immune response modulation primarily via T-cell regulation, has also been shown to be 
overexpressed in MPM. Similar to CS9, its expression correlates with histology and 
improved OS in MPM patients after CHT [180]. Aquaporin 1 (AQP1) expression by 
IHC was analyzed in two independent MPM cohorts. Higher AQP1 expression was 
associated with significantly longer OS in both cohorts in univariate and multivariate 
analysis [181]. The pro-inflammatory cytokine migration inhibitory factor (MIF) and its 
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receptor CD74 was examined in 135 MPM cases and showed significant association 
with of OS, with no such tendency for MIF [182]. 
Several studies investigated the prognostic role of different angiogenic molecules and 
variables in MPM [183]. For example, microvessel density (MVD) as measured by 
CD34 IHC was reported to be an independent prognostic marker in a study of 93 MPM 
patients [184].  
MPM cells are characterized by sustained proliferation, pro-survival signaling and 
reduced apoptosis. For example, O'Kane et al. investigated the expressions of p53 and 
anti- and pro-apoptotic b-cell lymphoma-2 (Bcl-2) family members by IHC in 54 MPM 
patients. p53 was overexpressed in 81% of the cases with heterogenous expression of 
pro- and anti-apoptotic Bcl-2 family members and furthermore no influence on survival 
[185]. Additionally, high cyclooxygenase-2 (COX-2) and low p21 and p27 expressions 
were associated with significantly shorter OS in a study analyzing 77 MPM patients 
with IHC [186]. In another recent study, our collaborators from Zurich reported high 
Ki-67 and p-S6 MPM tissue expressions as measured by IHC. pS6, a downstream 
molecule in the PI3K pathway, was associated with poor survival only in chemo-naïve 
MPM, whereas high Ki-67 expression remained associated with shorter PFS also in 
post-chemotherapy specimens [187]. Furthermore, it has been recently demonstrated 
that a systemic proinflammatory status is also associated with a more aggressive 
biological behavior reflected by elevated Ki67 index and VEGF expression in MPM 
tumor tissues [188]. 
Biological behavior and response to chemotherapy might be influenced by dysregulated 
DNA repair mechanisms, frequently detected in cancer cells [189]. One of the most 
investigated molecules in this regard is the excision repair cross-complementation group 
1 (ERCC1). ERCC1 belongs to a group of proteins which remove cisplatin-induced 
DNA adducts, thereby mediating drug resistance. Lower protein expression of 
thymidylate synthase (TS), the cellular target of pemetrexed, significantly correlated to 
longer time to progression and OS in univariate and multivariate analyses investigating 
60 MPM patients after pemetrexed treatment. No such association was observed for 
ERCC1 in 45 patients after cisplatin treatment or for TS in patients without pemetrexed 
therapy [190]. However, in another more recent study, ERCC1 protein expression was 
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significantly related to shorter OS. In the same study, both ERCC1 expression and 
ERCC1 codon 118 polymorphisms were related to PFS [191]. 
In summary, as shown by the aforementioned examples of prognostic tissue biomarkers, 
predicting treatment response and identifying reliable prognostic factors remains 
difficult in MPM. The majority of these reports consists of single-center experiences, 
some of which may have been certainly of insufficient power. For some specific 
biomarkers, which were investigated by several groups, results are often conflicting. 
Differences in case distribution based on gender, histology, stage and treatment, as well 
as different methodology, have likely contributed to these discrepancies [172].  
 
2.1.7.1 KI-67 
The rate of tumor proliferation has long been considered to be related to malignant 
behavior and thus estimation of tumor cell proliferation has been used as an important 
adjunct to histopathological diagnosis [192]. A simple and easily applicable method to 
evaluate tumor cell proliferation is a count of mitotic figures, which showed to be 
associated with prognosis in several solid tumor types [193, 194]. However, as mitotic 
counts only reflect one part of the cell cycle (the M-phase) but not the length of this 
phase, they are not completely reliable and reproducible. 
Ki-67 (a nuclear protein detectable in all phases of the cell cycle but absent in G0 cells) 
was originally defined by the prototype monoclonal antibody Ki-67. This antibody was 
generated by immunizing mice with nuclei of a Hodgkin lymphoma cell line (L428). 
The name is derived from the city of origin (Kiel, Germany) and the number of the 
original clone in the 96-well plate [195]. As the antigen of the Ki-67 antibody was not 
fully characterized in 1983, it was referred to as the Ki-67 antigen [196]. Soon, the Ki-
67 antigen was identified as a nuclear protein, associated with cellular proliferation and 
ribosomal RNA transcription [197]. To date, however, the exact molecular mechanisms 
of the Ki-67 protein are still not fully understood.  
The characterization of the Ki-67 antibody revealed interesting staining patterns, as it 
has shown to be reactive only in proliferating cells (Figure 17) [195]. Hence, it soon 
became evident that it is an excellent marker to determine the fraction of proliferating 
cells in a given cell population and was increasingly used as a diagnostic tool in 
different tumor types [198]. Moreover, mitotic rate, as measured by Ki-67 index, was 
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found to be prognostic in a number tumor types, including thoracic malignancies such 
as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [198, 199]. 
Moreover, it was found to be prognostic in peritoneal mesothelioma [200]. 
 
 
Figure 17: Phase-specific distribution of cell cycle biomarkers in LADC. Ki-67 is expressed during all 
phases of the cell cycle except the G0 phase. Adopted from [201] 
In addition, mitotic index is a well-established parameter for the grading of pre-
neoplastic bronchial lesions and used to classify neuroendocrine tumors of the lung 
[202, 203]. Ki-67 proliferation index was also investigated for diagnostic impact in 
paraffin-embedded cell blocks of pleural and peritoneal effusions, but failed to show a 
difference between reactive mesothelial hyperplasia and MPM [204]. The mitotic index, 
however, was shown to differ significantly between MPM patients with short- and long-
term outcome in several studies [205-207]. A recent study proposed a nuclear grading 
system including nuclear atypia and mitotic count for estimating prognosis in 
epithelioid MPM [208]. In this study, the combination of nuclear atypia and mitotic 
count was found to be a stronger discriminator of survival than all currently available 
clinicopathological factors. Moreover, there was a strong correlation with the time to 
recurrence after surgical treatment. Another recent study could additionally demonstrate 
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that high Ki-67 index was related to significantly shorter PFS and OS in chemonaive 
patients and that it also remained associated with shorter PFS and OS after 
chemotherapy [187]. 
However, Ki-67 has still not been validated as a reliable prognostic biomarker for MPM 
in large international sample collections. Therefore, one of our aims was to examine Ki-
67 as a potential independent and reproducible prognostic tissue biomarker in human 
MPM.  
 
2.1.8 Prognostic circulating biomarkers in MPM 
Circulating blood-derived inflammatory or tumor-associated biomarkers were among 
the first factors predicting poor prognosis in MPM besides stage and histology. 
Proinflammatory markers include white and red blood cell count, thrombocytosis, and 
more recently, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio 
(PLR) and the modified Glasgow Prognostic Score (GPS), consisting of CRP and its 
negative acute phase response counterpart, albumin [209]. Other circulating markers 
related to dismal prognosis in MPM in different scoring systems include high serum 
lactate dehydrogenase (LDH) level, anemia and leukocytosis [210]. In addition, our 
study group identified a prognostic and, furthermore, predictive value for increased 
CRP as well as elevated fibrinogen in patients with MPM [102, 103]. By analysis of the 
IASLC database, which to date represents the largest and most comprehensive 
collection of MPM patient data, others found that high platelet and leucocyte count 
were significantly related to poor OS, independently from other main clinical prognostic 
parameters [211]. Moreover, low serum albumin levels were recently shown to be 
associated with poor OS in two retrospective studies [145].  
All the aforementioned markers might somehow reflect the tumor burden and regulatory 
mechanisms related to the progression of the disease and thus they might act as 
surrogate parameters reflecting the patients overall condition. Nevertheless, these 
molecules are not directly associated or secreted by malignant cells. In recent years, 
research has increasingly focused on tumor-associated circulating biomarkers, which 
might have therapeutic impact in the future. The prognostic and predictive effect of 
VEGF serves as a good example of how circulating tumor-associated biomarkers could 
guide therapy in the future and help to select patients more likely to benefit from anti-
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angiogenic treatments. The intrinsic complexity of neo-angiogenesis, and its redundant 
regulatory mechanisms, suggests that multiple and different biomarkers are needed to 
predict the efficacy of anti-angiogenic agents and to monitor their biological and 
therapeutic effects [212]. The predictive role of pre-treatment VEGF levels have been 
investigated in two parallel phase II studies in patients with advanced MPM treated with 
thalidomide alone or combined with cisplatin/gemcitabine [213]. This study 
demonstrated increased survival in patients with low VEGF levels eight weeks post 
treatment. Change in circulating VEGF levels over the first 8 weeks of treatment was 
also predictive for survival. When pre-treatment VEGF was >median, decreasing VEGF 
was associated with increased survival. Another study demonstrated that patients with 
MPM had significantly higher serum levels of VEGF than those exposed to asbestos but 
had not developed MPM. In the same study, patients with advanced-stage MPM showed 
higher levels of VEGF than those with early-stage disease The difference in OS 
between the groups with high and low VEGF serum levels was significant [214]. 
Furthermore, it was demonstrated that patients with MPM had significantly higher 
pleural effusion VEGF levels those with non-malignant pleuritis or lung cancer 
spreading to the pleural space. Moreover, patients with advanced-stage MPM were 
reported to have higher circulating VEGF levels than those with early-stage tumors 
[215]. However, whether circulating VEGF concentrations could serve as prognostic 
biomarkers or predict bevacizumab efficacy in MPM remains controversial. A 
randomized phase 3 trial conducted by Zalcman et al. showed that high plasma VEGF 
concentrations were associated with worse PFS and OS [113]. Most interestingly, 
patients with baseline plasma VEGF concentrations lower than the median value had a 
5.2 month longer OS with cis/pem/beva than with cis/pem, whereas patients with higher 
baseline VEGF concentrations than the median value treated in the cis/pem/beva group 
showed a modest benefit in OS only. These results warrant further evaluation of blood 
VEGF levels as a prognostic and predictive marker for anti-VEGF targeted therapy in 
combination with other biomarkers. 
Mesothelin is a membrane bound protein expressed by normal mesothelial, MPM as 
well as ovarian and pancreatic cancer cells. Its potential role for early diagnosis and 
monitoring treatment response has been extensively investigated [216, 217]. Higher 
levels of serum-soluble mesothelin family proteins (SMRP) were associated with 
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significantly shorter OS in MPM patients [218]. A study evaluating mesothelin as a 
predictive factor for disease progression found significantly higher serum SMRP levels 
in patients with relapse/progression of MPM compared to newly diagnosed patients. 
Higher SMRP levels also significantly correlated to OS in univariate and multivariate 
analyses, but lost their significance when analyzed in the subcohort of epithelioid 
patients [219]. 
Fibulin-3 is a member of the extracellular glycoprotein fibulin family. Its gene 
expression is low in healthy tissues with the highest expression in the thyroid gland 
[220]. Fibulin-3 is related to cell adhesion, communication and growth, and has variable 
angiogenic effects [221, 222]. It has been shown to be up-regulated in metastases from 
pancreatic adenocarcinoma [223]. A recent study showed that plasma fibulin-3 levels 
can distinguish asymptomatic asbestos-exposed individuals from MPM patients and that 
pleural effusion fibulin-3 levels differentiates MPM effusion from other malignant or 
benign effusions. Furthermore, plasma fibulin-3 levels were significantly associated 
with OS [224]. However, another recent study including data from our study group 
showed a similar association of fibulin-3 levels with OS in two MPM cohorts but no 
diagnostic power [225].  
In summary, similar to tumor tissue-associated biomarkers, a variety of circulating 
biomarkers in MPM has been investigated in different subcohorts worldwide. However, 
the prognostic power of these markers varies among studies and only a few ones have 
shown to be reproducible. Hence, larger international studies are urgently needed in 
order to identify reliable markers to select patients for individual treatment options from 
which they might eventually benefit from. 
 
2.1.8.1 Complement component 4d (C4d) 
The complement cascade is a major component of the innate immunity and it essentially 
contributes to immune surveillance, cell homeostasis and tissue regeneration [226, 227]. 
It promotes inflammation and damages invaders such as microbes or foreign cells by 
activating a cascade of more than 30 fluid-phase and cell-associated proteins [228]. The 
development of antibodies against the own host tissue may lead to complement 
activation-related tissue injury, as it has been described in many auto-immune diseases. 
Accordingly, specific compounds are currently under investigation in order to interrupt 
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or hamper complement-related immunresponses [229, 230]. Three main pathways for 
activation are recognized: the classical, alternative and lectin pathways (Figure 18). The 
classical pathway is activated by binding of the antigen with a specific antibody. 
Immunoglobulin M (IgM), IgG3 and IgG1 are the most efficient activators of the 
classical pathway. Apart from classical antigen-antibody contact, the classical pathway 
can also be directly activated by other factors such as microorganisms, DNA, CRP, 
polyanionic molecules or apoptotic cells [228]. Further activation of C3a and C5a leads 
to the formation of the membrane attack complex (MAC) consisting of the complement 
factors C5b-C9. MAC is deposited on the target surface with penetration of C9 (the 
terminal component) into to the lipid layer of the target cell's membrane. This generates 
pores into the target membrane causing cell death via disruption [231].  
The lectin pathway is triggered by binding mannan-binding lectin (MBL - a C-type 
lectin) to terminal sugars on the surface of microorganisms [232]. MBL is structurally 
related to C1q, being the first step of compliment activation in the classical pathway. In 
the circulation, MBL associates with MBL-associated serine protease 1 (MASP1), 
MASP2 and MASP3. Binding of the MBL-MASP complex to the target cell's 
membrane leads to C4 and C2 cleavage, resulting in activation of C3, similar to that of 
the classical pathway. 
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Figure 18: Complement cascade activation pathways: Classical, lectin (MBL) and alternative pathways. 
C4 is activated by the classical and lectin pathway. Adopted from [226] 
Activation of the alternative pathway does not rely on antibodies for antigen recognition 
[228]. It is triggered by slow hydrolysis of circulating C3, referred as “C3 tickover”. 
Generated C3b is further activated by binding of alternative-pathway-specific proteins 
factor B, factor D and properdin. Binding of additional C3b to the alternative pathway 
C3 convertase renders it capable of C5 cleavage, and forms the basis for the 
amplification loop of the alternative pathway [229]. C3b can then generate the MAC by 
interacting with polysaccharides or proteins on the surface of microorganisms or 
endotoxins [233]. 
As shown in Figure 18, all complement activation pathways merge with C3b deposition 
on a target. As C3b acts as an additional activating factor of the alternative pathway, 
complement activation can be initiated by the classical or lectin pathway and amplified 
by the alternative pathway [229]. Moreover, a number of bypass pathways has been 
described [234]. 
Importantly, there is mounting evidence that the complement cascade, apart from auto-
immune diseases, is also involved in cancer development and progression by facilitating 
cellular proliferation and regeneration [226, 235-238].  
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Figure 19: Potential oncogenic roles of complement proteins. Adopted from [226] 
Organs chronically exposed to extrinsic toxins such as asbestos or tobacco eventually 
develop inflammation. Notably, chronic inflammation is a well-established risk factor 
of MPM and lung cancer [239]. Previous studies have raised the possibility that 
although acute inflammation interferes with malignant transformation, chronic 
inflammation promotes carcinogenesis [240]. Complement system activation in acute 
inflammation is a well-established concept, however, also chronic inflammatory 
diseases might play a role in triggering and consumption of these proteins [241]. C3a 
and C5a, for instance, are some of the most powerful proinflammatory molecules, and 
recent findings have demonstrated that these proteins may aid tumor growth through 
immunosuppression [242].  
Compliment activation promotes cellular proliferation and neoplastic spread by a 
variety of mechanisms (Figure 19). Activation of complement system proteins promotes 
oncogenesis by increasing mitogen signaling pathways via C3a and C5a binding and 
activation of PI3Kinase, Akt and mTOR [243]. Furthermore, MAC has shown to 
activate the cell cycle and specific oncogenic molecular machineries, such as ERKs, p38 
MAPKs, JNKs or PI3Kinase [226] [244]. Additionally, complement related proteins 
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(especially C3, C6 and MAC) have been shown to prevent cell death by exerting pro-
survival, pro-angiogenic and anti-apoptotic effects [245]. Complement proteins also 
reorganize intra- and extracellular matrix connections and thus facilitate invasion and 
migration [246]. Finally, the complement system plays an important role in the tumor 
microenvironment and promote immunosuppression and cancer growth [247]. 
 
A specific complement-related protein is the degradation protein C4d, a stable cleavage 
product of complement protein C4. C4d accumulates following both classical and lectin 
pathway activation [248-250]. C4d deposition in a tissue is regarded as an indirect proof 
of an activation of the complement cascade [249]. C4d is usually bound stably to the 
target structure but may eventually enter the circulation. Of note, C4d is routinely used 
as a tissue biomarker to investigate allograft tissue rejections in kidney transplants [249-
251]. C4d has also been found to have a prognostic role in different types of cancer 
[248, 249, 252]. Of note, it was recently reported that lung cancer cells produce C5a, a 
potent proinflammatory mediator creating a favorable microenvironment for tumor 
progression [253]. Ajona and colleagues found increased C4d levels both in plasma and 
bronchoalveolar lavage (BAL) samples from LADC patients. In this study, patients with 
elevated circulating as well as tumor tissue C4d levels had worse prognosis [248, 252]. 
Furthermore, C4d expression was associated with stage or dismal outcome in different 
other tumors such as astrocytomas and oropharyngeal squamous cell cancer [249, 254]. 
To date, there is limited information on the role of the complement activation in 
asbestos-related diseases and development of MPM. In 2002, a cohort of patients with 
or without pleural calcifications (PCs) due to prior asbestos exposure was investigated. 
C4 was only present in BAL samples of patients with PCs but not in those without PCs. 
Although PCs might trigger MPM development via chronic inflammation and immune 
response, subjects with PCs were assumed to develop MPM less frequently [255]. 
Zerva et al. investigated several factors associated with humoral immunity in patients 
environmentally exposed to asbestos. Asbestos-exposed individuals had significantly 
increased serum C3 levels independently of the presence of PCs when compared to 
healthy controls. Although C3 is the target protein of activated C4, serum C4 levels did 
not differ between these groups [256]. Unfortunately, the authors did not provide any 
data on the on the activation marker C4d. By analyzing MPM pleural effusions, Nabil et 
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al. demonstrated that complement factor H, a restrictive cofactor for the cleavage of 
C3b, potentially recruits monocytes and granulocytes to the malignant site via 
chemotactic function and thus supports malignant cell phagocytosis [257]. Despite all 
these efforts in elucidating the role of complement activation in human MPM, no study 
has yet focused on the prognostic or predictive role of C4d as a marker for complement 
activation in this disease. 
 
2.1.8.2 Activin A 
Activins are cytokines of the TGF-beta super-family of growth and differentiation 
factors [258] and were named according to their first identification as activators of 
follicle-stimulating hormone (FSH) release from pituitary cells [259, 260]. Activins are 
formed via the covalent intracellular dimerization of two subunits [261]. Five different 
human subunits have been identified (beta A, beta B, beta C and beta E). Multiple 
biological functions of Activin A (ActA) have been described, including essential roles 
in mesoderm induction [262], stem cell biology [263], reproductive biology [264], 
erythroid differentiation [265], systemic inflammation [266], cell death induction [267], 
wound healing [268] and fibrosis [269]. Because of ActA activation, receptor-regulated 
Smads (R-Smads) 2 and 3 are recruited to the receptor complex and phosphorylated by 
the type I receptor. Together with co-factors, Smads are involved in the regulation of 
gene expression. Important ActA target genes include p15INK4B [270, 271] and the 
lipid phosphatase SHIP(1) [272]. Moreover, there might be a role of a Smad-
independent signaling of ActA via activation of the MAP kinases ERK 1/2 and p38 
[273] as well as the PI3Kinase / Akt pathway [274]. Rho and JNK were also found to be 
stimulated by ActA [275]. Under physiological conditions, activin signaling is kept 
under stringent control by a number of different mechanisms. Besides regulated 
expression of different activin beta subunits, the extracellular activin-binding proteins 
follistatin and follistatin-related gene (FLRG), antagonistic co-receptors like BAMBI 
and Cripto and inhibitory Smad (I-Smad) 7 are important negative regulators of activin 
signaling (Figure 20) [276, 277]. 
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Figure 20: Graphic model of ActA signaling. (A) ActA transduces signals to the cell nucleus via type II 
and type I activin receptors and Smad proteins. (B) Under physiological conditions ActA signaling is 
strictly controlled by several mechanisms: (i) extracellular binding proteins for ActA like follistatin or 
FLRG can block interaction of ActA with activin receptors; (ii) expression of inhibitory co-receptors like 
BAMBI can block receptor activation; (iii) intracellular proteins interacting with the Smad pathway can 
modulate ActA signals. All these levels of control can become deregulated during carcinogenesis. 
Adopted from [276] 
ActA is critically involved in cellular differentiation and homeostasis in multiple 
organs. ActA induces growth arrest and apoptosis in several non-transformed cell types. 
For example, ActA is essential for maintaining a physiological balance between cell 
proliferation and cell death by limiting replication in hepatocytes [258]. Deregulated 
activin signaling has been found in a broad range of malignancies [278-281]. A recent 
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study demonstrated that ActA is overexpressed in both LADC and squamous cell 
carcinoma tissue and, furthermore, that NFkB-dependent upregulation of ActA is 
associated with cancer progression and metastasis [282]. Also, in esophageal carcinoma, 
a recent report demonstrated that elevated tumor tissue ActA expression is associated 
with lymph node metastasis and decreased survival [280]. Importantly, activin signaling 
has also been investigated as a potential new therapeutic target in different cancer types 
[281]. 
ActA is secreted to the blood and can be detected in the serum or plasma by ELISA 
(ELISA). Its circulating levels have been investigated in a variety of human 
malignancies including hepatocellular, breast, prostate, ovarian, oral, esophageal, 
pancreatic and lung cancers and multiple myeloma [283-291].  
With respect to thoracic malignancies, our group has recently demonstrated that also 
MPM cells overexpress ActA [292]. ActA increased MPM cells' proliferation and 
migration whereas inhibition of activin receptors by pharmacological inhibitors or 
siRNA-mediated silencing of ActA expression decreased their growth and survival. Our 
data on ActA in MPM were recently confirmed and extended to the closely related 
growth factor activin B by another group [293]. Thus, in MPM, similar to reports in 
NSCLC [294] and esophageal carcinoma [295, 296], ActA is associated with malignant 
behavior. Moreover, our group has recently shown that circulating ActA levels are 
elevated compared to healthy controls and correlated with disease stage and survival in 
LADC [297]. Therefore, we decided to study circulating ActA as a biomarker in MPM. 
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Figure 21: A previous study of our group on ActA and LADC. Serum ActA levels are elevated in patients 
with LADC and correlate with tumor progression. A.) ActA concentration is significantly higher in blood 
samples of patients with LADC (p = 0.015, vs. controls). B., C., D.) T and N status- and stage-dependent 
increase of serum ActA in LADC (*p < 0.05, **p < 0.01, ***p < 0.001) [297] 
 
Figure 22: Our previous study on ActA and LADC. Kaplan-Meier curves for OS of LADC patients 
according to serum ActA level (cut-off value is the median). LADC patients with high serum ActA levels 
had significantly shorter OS than those with low serum ActA levels (median OS was 7.9 vs. 39.6 months, 
HR: 0.2768, 95% CI 0.1450 to 0.5286; p < 0.0001) [297] 
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3 Objectives 
Based on the current literature and on the previous findings of our MPM study group, 
we intended to investigate the prognostic and predictive value of specific tissue and 
circulating biomarkers using large cohorts of blood and tissue samples collected in our 
clinic at the Medical University of Vienna and through our well-established 
international cooperation with centers specialized in the treatment of this devastating 
disease.  
 
3.1 Ki-67 index as a prognostic parameter in MPM 
Ki-67 has still not been validated as a reliable prognostic biomarker for MPM in large 
international sample collections and thus validation studies are needed to prove the 
independent and reproducible prognostic power of this tissue biomarker. Accordingly, 
we aimed to investigate whether Ki-67 index as determined by immunolabeling of 
MPM tissue sections is an independent and, furthermore, reproducible prognostic factor 
in a large international cohort of MPM samples. We further aimed to study the 
prognostic power of Ki-67 index compared to other well-established prognostic factors 
in an independent cohort of MPM patients. 
 
3.2 Circulating C4d as a prognostic biomarker in MPM 
Despite efforts in elucidating the role of complement activation in human MPM, no 
study has yet focused on the prognostic or predictive role of C4d as a marker for 
complement activation in this disease. 
Since the complement degradation product C4d has been shown to have a strong 
prognostic relevance in LADC, we aimed to investigate the tissue and circulating levels 
of C4d in MPM patients and thus compared these data with tumor load, chemotherapy 
response and clinicopathological parameters. We additionally assessed the impact of 
chemotherapy on circulating C4d levels and also evaluated the potential prognostic 
relevance of C4d levels on OS. 
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3.3 Circulating ActA as a prognostic parameter in MPM 
Circulating ActA has been shown to correlate with OS in LADC, but no data were 
available on the prognostic impact of circulating ActA levels in MPM. Thus, we aimed 
to analyze ActA plasma levels in MPM patients and compared them to clinical, 
radiological and pathological parameters and assessed the prognostic value of ActA in a 
large cohort of MPM patients. 
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4 Methods 
4.1 General ethical considerations 
Tumor tissue, blood samples and patient data described in chapters 3.1 - 0 (objectives) 
were collected in the following institutions: 
- Division of Thoracic Surgery, Medical University of Vienna, Austria (AUT) 
- National Koranyi Institute of Pulmonology, Budapest, Hungary (HUN) 
- Department for Respiratory Diseases Jordanovac, School of Medicine, 
University of Zagreb, Croatia (CRO) 
- Department for Pulmonology, University Clinic Golnik, Slovenia (SLO) 
- Concord Repatriation General Hospital and Strathfield Private Hospital in 
Sydney, Australia (AUS) 
All of the included patients provided written informed consent to the collection of the 
biological material and the collection of the clinical data. Analyses of these data and 
materials were approved by all local ethical committees. No individual patient data is 
identifiable in the respective publications or in this thesis. All methods included in this 
thesis were performed in accordance with the relevant guidelines and regulations. All 
experiments that were reported in this thesis were done complying with all mandatory 
laboratory health and safety procedures. 
 
4.2 Evaluation of Ki-67 index as a prognostic parameter in MPM 
4.2.1 Study population 
In order to evaluate Ki-67 IHC in MPM, we investigated 285 patients. The test cohort 
consisted of 187 patients from three institutions. 91 patients were included in CRO. The 
HUN cohort consisted of 42 cases. 54 cases were included in AUT. In addition, 98 
patients from SLO were analyzed as an independent validation cohort. All patients were 
referred to one of the four institutions between 1994 and 2012. Inclusion criteria were 
complete clinical data and reliable follow-up and available representative paraffin-
embedded tumor tissue. MPM diagnosis was histologically proven during clinical 
routine work-up in all cases. The IMIG staging system was routinely used for clinical 
and pathological tumor staging [95]. All tissue samples were collected during surgery 
(n=71) or as part of diagnostic work-up.  
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The CRO cohort consisted of 85 epithelioid and 6 non-epithelioid cases. Forty-six 
patients were treated by chemo and/or radiotherapy and 29 by best supportive care. 
Twelve patients received surgery in curative intent. In 4 patients, information about the 
applied treatment was unavailable in the medical records.  
In the 42 HUN cases, only three patients received surgery within a multimodality 
treatment protocol and two additional patients were treated by surgery alone. Epithelioid 
morphology was most frequently identified (n=33). 
In the AUT cohort, all 54 patients received MCR. EPP was performed in the majority of 
cases (n=52), as previously described [169]. One patient underwent P/D, and 1 received 
local MCR followed by adjuvant radiotherapy. All tumor samples were collected during 
surgery. Thirty-six patients received a combination of surgery with adjuvant and/or 
neoadjuvant treatment (multimodality treatment group). 29 patients (53.7%) received 
induction chemotherapy before surgery and 23 patients (42.6%) were treated with 
adjuvant therapy after resection (radiation: n=10, chemotherapy: n=8, chemo-radiation: 
n=5). Eighteen patients were treated with surgery alone (surgery-alone group). The most 
frequent histological subtype was the epithelioid (n=38). 57% had pathologically 
classified late stage disease according to the postoperative report (stage III and IV; 
n=31). 
As an independent validation cohort, 98 SLO patients were included to re-evaluate Ki67 
as a reproducible prognostic marker. For the SLO cohort, we used the median Ki67 
expression as a cutoff as later described because the tumor samples were scored by an 
independent pathologist different than the one in the test cohort. Epithelioid subtype 
was the most frequent (n=77) followed by biphasic tumors (n=15). 
 
4.2.2 Tumor samples, staining, scoring and blood biomarkers 
All tumor samples were fixed in formalin and embedded in paraffin (FFPE). One 4-μm 
section from a representative, tumor-rich FFPE block was stained by hematoxylin/eosin 
(HE) to confirm and locate areas of definitive tumor content and consecutive sections 
were used for Ki67 IHC. Sections were deparaffinised with xylene and rehydrated with 
decreasing alcohol concentrations. After heat-induced epitope retrieval in citrate buffer 
(10 mmol l−1, pH 6.0), slides were incubated at room temperature with the Ki67 
antibody (monoclonal mouse antibody, Dako Cytomation (Dako, Glostrup, Denmark), 
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clone MIB-1, dilution 1 : 100, incubation time: 30 min). Antibody binding was detected 
by means of the UltraVision LP detection system (Lab Vision Corporation, Fremont, 
CA, USA) according to the manufacturer’s recommendations. Color development was 
achieved by 3-3-diaminobenzidine. Finally, all analyzed slides were counterstained with 
Mayer’s hematoxylin. 
 
Ki-67 scoring 
Evaluation of IHC staining was independently performed by one pathologist in the test 
cohort (AUT/CRO/HUN) and by another independent pathologist in the validation 
cohort (SLO). They had no information about the clinical history of the cases as they 
only received anonymized slides for evaluation and scoring. Both pathologists scored 
the HUN cohort to test the inter-observer reproducibility. Counting was limited to 
proven tumor tissue and only nuclear staining was scored as positive. First, the whole 
tissue section was reviewed at low magnification to identify the regions with the highest 
viable tumor cell content. The hot-spot approach was used to measure areas with the 
highest proliferative activity. Whenever possible, up to 10 high-power fields were 
analyzed and at least 500 tumor cells were counted to calculate the mean percentage of 
Ki67-positive tumor cells per analyzed sample. 
 
4.2.3 Statistical analyses 
Metric data is always given as median and corresponding range, or, in case of survival, 
as median and corresponding 95% confidence interval (CI) if not otherwise indicated. 
OS was defined as the time between MPM diagnosis and death or between diagnosis 
and last follow-up date. Survival was analyzed by the Kaplan–Meier method and log 
rank test or by the Cox-regression model to calculate hazard ratios (HRs) and 
corresponding CIs. In the test cohort, patients were divided into high and low Ki67 
index groups by the median (15%). Since the validation cohort was scored by a different 
independent pathologist, we again used median Ki67 expression of the validation group 
(22%) for dichotomizing into the low (n=52) and high Ki67 (n=46) expressing groups. 
An unpaired t-test was used to compare the mean of parametric distributed metric data 
between two groups and one-way ANOVA to compare the mean within more than two 
groups, respectively. Mann–Whitney U-test was used for non-parametric distributed 
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metric data. χ2-test was performed for analyzing the association between categorical 
factors. The correlation of metric data was analyzed by Pearson’s correlation 
coefficient. Receiver operating characteristic (ROC) analysis was performed in the 
epithelioid subtype of the full cohort with a follow-up of >12 months (n=221) to 
investigate the sensitivity and specificity of Ki67 in predicting short-term survival using 
the median OS of 12 months as cutoff. 118 patients were analyzed for the NLR, 97 
patients for CRP and 127 patients for fibrinogen using cutoffs from the respective 
studies [102, 103, 298]. In addition, in 65 patients, all three aforementioned biomarkers 
were available and could therefore be directly compared with each other and to Ki67 in 
ROC analyses. All statistical analyses were calculated with the SPSS Statistics 18.0 
package (Predictive Analytics Software, SPSS Inc., Chicago, IL, USA). P-values are 
given as two-sided and were considered statistically significant below 0.05. 
 
4.3 Evaluation of circulating C4d as a prognostic parameter in MPM 
4.3.1 Study population 
Clinical data and plasma samples of 55 consecutive, histologically verified MPM 
patients were collected at the time of diagnosis (n=30) or before curative intent surgery 
after induction chemotherapy (n=25) at the center in AUT between May 2011 and 
December 2014. All patient blood and tissue samples were retrieved before any 
diagnostic or curative intervention or in case of post-chemotherapy samples before 
surgical resection. Patients with acute clinical infections were excluded from the study. 
In 12 patients, plasma samples at the time of diagnosis as well as before surgery were 
available, representing pre- and post-chemotherapy samples. Of 32 of these 55 patients, 
FFPE tissue specimens were collected for IHC analysis. Furthermore, plasma samples 
from an age-matched cohort of 21 healthy volunteers (HV) as well as from 14 patients 
diagnosed with non-malignant pleural diseases (NMPD) were included. 
 
4.3.2 Tumor and blood samples, staining and blood biomarkers 
32 FFPE MPM tissue specimens were collected and analyzed by C4d IHC. 
Additionally, we performed C1q IHC in 14 FFPE tissue specimens deriving from 
patients with high (n = 7) and low (n = 7) circulating C4d levels. After the sections were 
deparaffinized and rehydrated, endogenous peroxidase activity was blocked with 0.3% 
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H2O2 in phosphate buffered saline. Heat-induced epitope retrieval was performed by 
using TRIS/EDTA buffer (pH=9). Primary antibodies (anti-human C4d; Biomedica, 
Vienna, Austria and anti-human C1q; ab71089, Abcam, Cambridge, UK) were diluted 
1:500 and 1:1000, respectively, and incubated for 60 min at RT. Antibody binding was 
detected with the UltraVision LP Detection System (Lab Vision Corporation). Color 
development was achieved by DAB followed by hematoxylin counterstaining. All 
stainings were evaluated by a pathologist. 
Blood was collected via peripheral venous puncture from MPM patients and controls 
into 10 ml EDTA Vacutainers (BD Biosciences). Within 30 min after blood collection, 
centrifugation was performed. Plasma supernatant was stored in aliquots at -80°C until 
use. C4d and C3a fragments ELISA kits were purchased from Quidel (San Diego, CA, 
USA). For the analyses of C4d and C3a, samples were diluted 1:70 and 1:200, 
respectively, according to the manufacturers’ instructions. Standard curve generations 
and measurements in duplicates were performed according to the guidelines of the 
company. 
 
4.3.3 Tumor volumetry 
In 20 of 55 patients, tumor volumetry measurement was achievable. Volumetric 
analyses were performed in patients with digitally available CT imaging data before 
and/or following chemotherapy. Chest CT images were analyzed by using dedicated 
software featuring semi-automatic segmentation with linear interpolation, allowing 
manual adjustments if necessary (Myrian; Intrasense, Paris, France) - as previously 
described [299]. In summary, the segmentation and tumor volume quantification 
contained the following steps: the normal lung tissue, including bronchi and vessels, 
was marked semi-automatically by thresholding and region growing. Then pleural 
effusion and atelectatic lung areas were marked with a magnetic lasso function. After 
marking normal lung tissue and pleural effusion, atelectatic lung and the outer part of 
the pleura was segmented semi-automatically. By using a lineal algorithm, interpolation 
between the marked slices was applied automatically. Finally, tumor volume was 
calculated by multiplying the sum of the voxels. Data was independently analyzed by 
two radiologists.  
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4.3.4 Statistical analyses 
To investigate the role of circulating plasma levels of C4d, first we stratified our cohort 
by the cut-off of 3 µg/mL which was previously used in LADC [248]. Nevertheless, 
because only one patient had C4d plasma level above 3 µg/mL at time of diagnosis, this 
cut-off value proved to be not suitable for MPM. However, when we analyzed 
circulating C4d values of patients with early- and late-stage disease, we found a distinct 
separation when using 1.5 µg/mL concentration as a potential cut-off. We also found 
that 1.5 µg/mL level was the best cut-off in our cohort by performing ROC curve 
analysis and Youden’s Index calculation for twelve months’ survival (data not shown). 
Hence, calculations described below were performed by using 1.5 µg/mL as cut-off. 
Categorical data was compared by performing Fishers’ exact or chi-square tests. 
Statistical differences between two groups were tested by Mann-Whitney U test. The 
significance of potential correlations of continuous parameters was investigated by 
using Pearson correlation. OS was defined as time between initial MPM diagnosis and 
date of death or last follow-up. OS was estimated by the Kaplan-Meier method and a 
log rank test was used to calculate survival differences between two groups. A 
multivariate cox regression model was used to calculate hazard ratios and 95% 
confidence intervals for factors independently influencing OS. To investigate the 
accuracy of C4d as a predictor for survival and to distinguish between MPM and non-
malignant pleural disease, ROC curve analysis was used. For each cut-off point, the 
Youden’s Index was calculated (sensitivity + specificity). All results were considered 
statistically significant when p<0.05 two-sided. Analyses were performed using the 
SPSS Statistics 23.0 package (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.0. 
 
4.4 Evaluation of circulating ActA as a prognostic parameter in MPM 
4.4.1 Study population 
Thirty consecutive patients with blood withdrawn at the time of diagnosis were included 
at the institution in CRO between 2013 and 2014. Between 2011 and 2014, 62 
consecutive patients were included at the center in AUT with blood collected either at 
the time of diagnosis or before surgical resection or both. The center in AUS 
contributed 37 non-consecutive samples either from the time of diagnosis or following 
therapy (collected between 2009 and 2013). 16 patients who were diagnosed with 
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pleuritis or pleural fibrosis and demonstrated no sign of MPM were also included. 
Additionally, plasma samples were collected from an age- and gender-matched cohort 
of 45 healthy individuals. 
 
4.4.2 Blood samples 
Blood was collected by venous puncture from suspected MPM patients and healthy 
subjects into 10 ml EDTA Vacutainers (BD Biosciences). Centrifugation was performed 
within 30 min after blood collection. Plasma supernatant was stored in aliquots at −80 
°C. Quantikine ActA ELISA kits were purchased from R&D Systems (Minneapolis, 
MN, United States of America [USA]). Sample preparation, standard curve generation 
and measurement of samples in duplicates were performed according to the guidelines 
of the manufacturer. 
 
4.4.3 Tumor volumetry 
Tumor volumetry in this project was performed applying the same methods as described 
in chapter 4.3.3. 
 
4.4.4 Statistical analyses 
Statistical differences between two groups were tested by Mann-Whitney test unless 
otherwise stated. Kruskal–Wallis test was used with the post hoc Dunn-test for the 
comparison of more than two groups. The Bonferroni correction was calculated for the 
adjustment of the alpha type I error. Accordingly, in multiple comparisons the P-value 
was divided by the number of comparisons being made. In order to analyze the 
correlation of two parameters, Spearman-test was applied. OS was defined as the time 
between date of diagnosis and death, otherwise patients were censored at the time of last 
contact. Kaplan–Meier curves were used to demonstrate patients’ OS. Differences in OS 
were compared by the log-rank test. Prior to the performance of the multivariate 
analysis of the clinical parameters using the Cox regression model, the proportional 
hazards (PH) assumption was evaluated graphically by plotting the logarithm of the 
cumulative hazards functions for each covariate. The PH assumption was considered 
satisfied when the lines were approximately parallel and did not cross each other. 
Furthermore, interaction terms between plasma ActA levels and covariates were 
 - 68 - 
 
introduced to the multivariate model. Multiple imputation by chain equation (MICE) 
was employed to handle the missing data, in order to avoid the omission of valuable 
information. ROC curve analysis was used to assess the accuracy of fibrinogen and 
ActA levels to predict survival. The Youden index was calculated as (sensitivity + 
specificity)−1 to determine the optimal cut-off point. Differences were considered 
statistically significant when P < 0.05. All statistical analyses were performed using the 
PASW Statistics 18.0 package (Predictive Analytics Software, SPSS Inc., Chicago, IL, 
USA) and GraphPad Prism 5.0. 
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5 Results 
5.1 Ki-67 index as a prognostic parameter in MPM 
5.1.1 OS is influenced by treatment modality and histological subtype 
The test cohort consisted of 40 female (21.4%) and 147 male (78.6%) histologically 
verified MPM patients. 156 patients suffered from epithelioid MPM (83.4%) compared 
with 31 non-epithelioid MPM patients (16.6%) including 22 biphasic (11.8%) and 9 
sarcomatoid (4.8%) cases.  
Median OS in the test cohort was 12.0 months (CI 9.3–14.7). In univariate survival 
analyses, histology (Figure 23A) and treatment (Figure 23C) were found to have 
prognostic value. Gender, age and disease stage (Figure 23B) had no significant impact 
on OS in univariate survival analyses of the test cohort (Table 6). 
 
  
 
Figure 23: OS prognosticators in MPM. (A) The three histological subtypes are characterised by different 
outcomes (epithelioid 12.8 (CI 10.5–15.0) months vs biphasic 7.2 (CI 0–20.7) vs sarcomatoid 5.6 (CI 
2.5–8.7) months, P=0.005). (B) Disease stage had no significant impact on OS (late stage 10.8 (CI 7.3–
14.3) months vs early stage 15.4 (CI 13.1–17.8) months, P=0.305). (C) Treatment has robust prognostic 
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impact on OS (multimodality therapy 18.5 (CI 8.2–28.8) months vs chemo and/or radiotherapy 13.9 (CI 
9.6–18.3) months vs best supportive care (BSC) 7.6 (CI 4.4–10.8) months vs surgery alone 5.3 (CI 0.8–
9.7) months, P<0.001). 
Table 6: Univariate survival analyses in the test cohort (n=187). CI=confidence interval; HR=hazard 
ratio; OS=overall survival. a Two-sided log rank test. b Missing cases: n=30 (16.0%). 
Characteristics OS (CI) Pa HR (CI) 
Age, years 
≤61.5 12.2 (10.0–14.5) 0.84 0.97 (0.72–1.31) 
>61.5 10.3 (5.2–15.4) — — 
Sex 
Female 11.3 (9.6–13.0) 0.17 0.76 (0.51–1.13) 
Male 12.1 (8.6–15.6) — — 
Histology 
Epithelioid 12.8 (10.5–15.0) <0.01 1 
Biphasic 7.2 (0–20.7) — — 
Sarcomatoid 5.6 (2.5–8.7) — — 
Stageb 
Early stage 15.4 (13.1–17.8) 0.31 1.24 (0.82–1.87) 
Late stage 10.8 (7.3–14.3) — — 
Treatmentb 
Surgery alone 5.3 (0.8–9.7) <0.01 1.30 (0.76–2.21) 
Best supportive care 7.6 (4.4–10.8) — 1 
Chemo and/or radiotherapy 13.9 (9.6–18.3) — 0.61 (0.39–0.95) 
Multimodality treatment including radical 
surgery 
18.5 (8.2–28.8) — 0.46 (0.28–0.74) 
 
5.1.2 Ki67 index is not associated with histology and stage but significantly decreased 
in post-chemotherapy cases 
Next, Ki67 index was determined on tumor sections following IHC staining (Figure 24). 
In the HUN cohort, both pathologists scored the tissue slides to test the inter-observer 
reproducibility. The scoring by the two pathologists showed a strong and significant 
correlation (Pearson’s correlation coefficient: 0.668, P<0.001, n=41) and thus was 
considered to be reliable. 
The median percentage of Ki67-positive tumor cells was 15.0% (range: 0–60%) for the 
entire test cohort. Table 7 shows the main patient characteristics by Ki-67 index. There 
was no significant difference in the distribution of Ki67 index with regard to age, sex, 
histology or stage. Furthermore, there was no association with histology (Figure 24B). 
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Figure 24: Ki67 index in MPM tissue samples. (A) Ki67 nuclear staining in all three major histological 
subtypes of MPM. Scale bar is 100 μm. (B) There was no significant difference between the three 
histological subtypes with regard to Ki67 index (mean±s.d.: epithelioid 16.3±12.9 vs biphasic 18.3±15.3 
vs sarcomatoid 18.2±13.6, P=0.766). (C) Modest increase of Ki67 index in late stage of disease 
(mean±s.d.: 17.6±13.2) vs early stage (13.9±13.6, P=0.144). (D) Patients after induction chemotherapy 
had significantly lower amount of Ki67-positive tumor cells when compared with the treatment naïve 
patients in the test cohort (mean±s.d.: induction chemotherapy 10.5±8.5 vs chemo-naïve 18.3±13.9, 
asterisk denotes significance of P<0.001). 
Accordingly, the distribution of the histological subtypes within the high and low Ki67 
index groups did not differ significantly (Table 7). No association of Ki67 index and 
disease stage was found in the test cohort (Figure 24C). However, patients that were 
treated in a multimodality setting had lower Ki67 index when compared with those in 
other treatment groups. Accordingly, the Ki67 index was significantly lower in patients 
treated by induction therapy than others in the test cohort who had not received 
chemotherapy tissue retrieval (Figure 24D). 
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Table 7: Patient characteristics and distribution according to Ki67 expression in the test cohort (n=187). 
*=two-sided χ2-test; #=missing cases: n=30 (16.0%) 
 
Low Ki67 High Ki67 All patients 
  
Characteristics Numbers % Numbers % Numbers % P 
Age, Years 
61.5 50 53.2 44 46.8 94 50.3 NS* 
>61.5 45 48.4 48 51.6 93 49.7 — 
Sex 
Female 25 62.5 15 37.5 40 21.4 NS* 
Male 70 47.6 77 52.4 147 78.6 — 
Histology 
Epithelioid 81 51.9 75 48.1 156 83.4 NS* 
Non- Epithelioid 14 45.2 17 54.8 31 16.6 — 
Stage# 
early stage 22 64.7 12 35.3 34 21.7 NS* 
late stage 60 48.8 63 51.2 123 78.3 — 
Treatment# 
Surgery alone 12 46.2 14 53.8 26 16.6 0.02* 
Best supportive care 13 39.4 20 60.6 33 21 — 
Chemo and/or Radiotherapy 24 45.3 29 54.7 53 33.8 — 
Multimodal treatment 32 71.1 13 28.9 45 28.7 — 
Surgery# 
Surgery 44 62 27 38 71 45.2 0.02* 
No Surgery 37 43 49 57 86 54.8 — 
Induction Therapy# 
Induction 25 75.8 8 24.2 33 21 0.01* 
Chemo-naïve at sampling time 56 45.2 68 54.8 124 79 — 
 
5.1.3 Ki67 is an independent prognostic marker only in epithelioid MPM 
Outcome of MPM patients with high Ki67 index was significantly worse compared to 
the low Ki67 index group (median OS 7.5 vs. 19.1 months, HR 2.3, CI 1.7–3.2, 
P<0.001, Figure 25A) in univariate survival analyses. In multivariate survival analyses, 
Ki67 index remained to be a significant prognostic parameter (HR: 2.1, CI: 1.4–3.1, 
P<0.001) independently from histology (P=0.013) and treatment modality (P=0.001), 
whereas age, gender and stage had no significant independent prognostic impact on OS 
(Table 8). In subgroup analyses, Ki67 showed prognostic power only in the epithelioid 
subgroup (Figure 25B) whereas it had no prognostic impact in the non-epithelioid 
subtype (Figure 25C). In all other subgroup analyses (for age, gender, stage and 
treatment), Ki67 proved to be a prognostic marker in all except the surgery-alone 
subgroup. Moreover, Ki-67 proved to be a prognostic parameter in the validation cohort 
as well (Figure 25D). 
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Figure 25: Prognostic power of Ki67 index in MPM. (A) Kaplan–Meier survival analysis of the test 
cohort (n=187). There was a significant difference in the OS between patients with high (n=92) vs low 
(n=95) Ki67 index (HR 2.3, CI 1.7–3.2, P<0.001). Median OS was higher in low Ki67 index (<15%) 
group (19.1 (CI 11.7–26.5) months) than in patients with high Ki67 index (7.5 (CI 5.2–9.8) months, 
P<0.001)). (B) Kaplan–Meier survival curve shows that Ki67 is prognostic in epithelioid MPM. (C) In 
contrast, there is no impact of Ki67 index on OS in patients with non-epithelioid MPM (n=31). (D). 
Kaplan–Meier survival analysis in the validation cohort (n=98). Ki67 had a significant impact on OS 
(P=0.048) when using median Ki67 expression of the validation cohort as cutoff (22%). 
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Table 8: Cox-regression model adjusted for patient characteristics (n=149) 
Characteristics HR for death 95% CI P 
Age, years 
61.5 0.98 0.69–1.40 0.92 
>61.5 1 — — 
Sex 
Female 0.94 0.53–1.67 0.84 
Male 1 — — 
Histology 
Epithelioid 1 — 0.01 
Non-epithelioid 1.90 1.14–3.15 — 
Stage 
Early stage 0.64 0.36–1.12 0.12 
Late stage 1 — — 
Treatment 
Surgery alone 1.44 0.75–2.80 0.28 
Best supportive care 1 — — 
Chemo and/or Radiotherapy 0.58 0.36–0.93 0.02 
Multimodal treatment 0.52 0.30–0.91 0.02 
Ki67 Expression 
Low Ki67 1 — <0.01 
High Ki67 2.11 1.44–3.10  
 
5.1.4 Ki67 is an accurate marker predicting short-term survival in epithelioid MPM 
Next, we performed a ROC curve analysis to test the sensitivity and specificity for 
detecting early death within one year after diagnosis. For this analysis, all epithelioid 
MPM patients with clinical follow-up for at least 12 months (n=221) were included. 
Ki67 showed an area under the curve of 0.68 for predicting 1-year survival (Figure 
26A). The sensitivity and specificity at 15% Ki-67 positivity were 0.69 and 0.57, 
respectively. 
 
 
  
 - 75 - 
 
 
Figure 26: Sensitivity and specificity analyses of Ki67 by ROC analysis. (A) in all epithelioid MPM 
patients with follow-up of at least 12 months (n=221) showed an area under the curve of 0.68. The 
sensitivity and specificity at 15% (cutoff used in the test cohort) were 0.69 and 0.57, respectively. (B) 
Ki67 index, NLR, fibrinogen and CRP showed areas under the curve of 0.70, 0.72, 0.62 and 0.71, 
respectively (n=65). 
We further compared the ability of fibrinogen, NLR and CRP to predict 1-year OS in 
MPM patients with Ki67 and performed an additional ROC analysis. Ki67, NLR, 
fibrinogen and CRP showed similar areas under the curve of 0.70, 0.72, 0.62 and 0.71. 
(Figure 26B). 
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5.2 C4d as a circulating prognostic biomarker in MPM 
The clinicopathological parameters with regard to high and low plasma C4d levels of 
the entire patient cohort are presented in Table 9. A total of 34 patients (61.8%) 
underwent multimodality treatment, consisting of induction chemotherapy (platinum-
based) followed by MCR with or without IMRT. In 31 (91.2%) of these patients, EPP 
was performed. Neoadjuvant CHT was applied in 35 patients (63.6%) and consisted of 
three to four cycles of a platinum-based regimen. Fifteen patients (38.2%) received 
CHT and/or RT only due to advanced disease at the time of diagnosis.  
 
Table 9: Clinicopathological characteristics of MPM patients grouped by circulating C4d levels with a 
cut-off of 1.5 µg/mL. MMT, multimodal treatment; EPP, extrapleural pneumonectomy; CHT, 
chemotherapy; RT, radiotherapy; NA, not available 
    Total 
(n= 55) 
C4d low 
(n= 37) 
C4d high 
(n= 18) 
p 
Gender  Male 
Female 
40 
15 
28 
9 
12 
6 
0.529 
Age Mean ± SD 62.0 ± 12.3 64.6 ± 11.4 56.8 ± 12.6 0.02 
Smoker 
(NA = 9) 
Never 
Former 
Current 
15 
24 
7 
9 
17 
4 
6 
7 
3 
0.700 
Histology  Epithelioid 
Non-epi 
41 
14 
29 
8 
6 
12 
0.002 
IMIG Stage 
(NA = 11) 
Early (I/II) 
Late (III/IV) 
12 
32 
11 
18 
1 
14 
0.035 
Treatment 
(NA = 6) 
CHT/RT 
MMT  
15 
34 
9 
24 
10 
6 
0.028 
EPP 
 
Yes 
No 
31 
24 
23 
14 
8 
10 
0.255 
CHT 
(NA = 1) 
CHT 
No induction 
35 
19 
25 
11 
10 
8 
0.372 
 
5.2.1 Lack of tumor cell-specific expression of C4d 
We performed IHC of 32 MPM FFPE tissue specimens to assess C4d expression within 
tumor tissue. Interestingly, we found no tumor cell-specific C4d expression in these 
samples (Figure 27A). Therefore, correlations between circulating C4d plasma levels 
and tumor cell expression could not be performed. However, several germinal centers of 
ectopic lymphoid structures within the tumor strongly stained positive for C4d (Figure 
27B). 
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Figure 27: Tissue expression of C4d in MPM. (A) There was no C4d labeling found in MPM cells. Scale 
bar is 100μm (B) However, strong C4d expression was observed in the germinal center of ectopic 
lymphoid structures (scale bar 100μm). The plasma membrane specific labeling is demonstrated in the 
high magnification inset (scale bar 40μm). 
 
5.2.2 C4d plasma levels are not elevated in MPM patients compared to HV or NMPD 
To investigate the relevance of circulating C4d as a potential diagnostic biomarker, we 
compared C4d plasma levels of MPM patients (n=55), HVs (n=21) and with NMPD 
(n=14) (Figure 28A). Interestingly, we found no significant differences between these 
three cohorts.  
 
 
Figure 28: Plasma levels of C4d in MPM patients. (A) There were no significant differences between 
MPM patients and healthy volunteers (HV) or patients with non-malignant pleural disease (NMPD) in 
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their circulating C4d levels (MPM versus HVs: Mann Whitney U test, p=0.833; MPM versus NMPDs: 
Mann Whitney U test, p=0.851). (B) Within the MPM cohort, we found a non-significant tendency for 
higher C4d levels in non-epithelioid compared to epithelioid subtype (Mann Whitney U test, p=0.182). 
(C) Also, patients with advanced disease (stage III or IV) had the tendency to have higher circulating C4d 
plasma levels (Mann Whitney U test, p=0.079). (D) Comparison of radiologically assessed tumor 
volumetric data and circulating C4d levels. After dividing the cohort (cut-off 1.5 µg/mL), high C4d levels 
were significantly associated with a higher tumor load (366.7±72.7 versus 190.3±46.7 cm3, p=0.047). 
C4d levels were much more heterogeneous in MPM patients than in HV (18 (33%) 
MPM patients showed a C4d level above 1.5µg/mL - only 4 (20%) HVs had levels 
above 1.5µg/mL). MPM patients presenting with epithelioid subtype tended to have 
lower circulating C4d levels (Figure 28B). Moreover, patients presenting with advanced 
disease showed a tendency to have higher circulating C4d plasma levels when compared 
to patients with early-stage disease (Figure 28C). Interestingly, nearly all HV, NMPD as 
well as the majority of MPM patients had circulating C4d levels equal to or lower to our 
established cut-off of 1.5 µg/mL. Only a distinct subgroup of MPM patients had clearly 
increased circulating C4d plasma levels (Figure 28A).  
We also evaluated the association of C4d with main clinicopathological parameters 
including gender, age, smoking status and treatment regimen. Patients with epithelioid 
subtype, IMIG stage I/II, advanced age or those who underwent multimodality 
treatment were significantly more likely to have C4d levels below 1.5 µg/mL (Table 9). 
Notably, circulating C4d levels decreased significantly with advanced age, though with 
a weak correlation (Pearson r: -0.34; p=0.003). 
 
5.2.3 Correlation of C4d with CT-based tumor volumetry 
Circulating C4d correlated with disease stage and thus we evaluated the correlation of 
tumor load assessed by CT-based tumor volumetry with plasma C4d levels. Pre- and 
post-chemotherapeutic volumetric data were available for 20 patients. The average 
period between CT and blood collection was 21.5 days. After dichotomizing the sub-
cohort according to our established C4d cut-off (1.5 µg/mL), high circulating C4d levels 
were significantly associated with a higher tumor load (Figure 28D). When we directly 
correlated tumor volumetry with circulating C4d plasma levels, we found the non-
significant tendency that C4d increased with increasing tumor volume (Pearson r: 0.34; 
p=0.099).   
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5.2.4 Correlation of C4d with circulating inflammatory-based markers  
Based on the observation that C4d is expressed intratumorally within ectopic germinal 
lymphoid structures, we correlated C4d with well-known inflammation-related 
biomarkers. Higher circulating C4d levels were associated with higher plasma levels of 
fibrinogen (Figure 29A) and CRP (Figure 29B). We detected no correlation between 
C4d and white blood count (WBC) (Figure 29C). 
 
  
 
Figure 29: Correlations of circulating C4d levels with other inflammatory-related biomarkers. Strong 
correlations were found between circulating fibrinogen (A) as well as CRP (B) and circulating C4d levels 
in MPM patients (Fibrinogen: Pearson r: 0.48; p=0.001; CRP: Pearson r: 0.44; p=0.002;). (C) In contrast, 
WBC did not correlate with circulating C4d plasma level (Pearson r: -0.14; p=0.697). 
 
5.2.5 Plasma levels of C4d predict chemotherapeutic response after induction 
treatment 
Next, we investigated the effect of CHT on circulating C4d levels and evaluated C4d 
values of patients following platinum-based neo-adjuvant chemotherapy. Interestingly, 
patients with stable disease or progressive disease (SD/PD) after CHT had significantly 
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higher C4d levels compared to those with a partial or major response (Figure 30A). In 
contrary, inflammatory-based markers including fibrinogen and CRP showed no 
significant correlation with chemotherapeutic response.  
 
  
Figure 30: Circulating plasma level of C4d correlates with chemotherapy response and prognosis in MPM 
patients. (A) Following induction chemotherapy, patients with partial or major response (PR/MR) had 
significantly lower circulating C4d values when compared to patients with SD/PD (0.52±0.13 versus 
2.02±0.42 µg/mL, p=0.005). (B) Kaplan-Meier survival curve of all MPM patients with plasma samples 
collected at time of diagnosis (n=30). After dividing the cohort (cut-off 1.5 µg/mL) into low (n=21) and 
high (n=9) C4d plasma levels, those with low plasma C4d had significantly shorter OS (HR 7.33, CI 1.71 
– 31.44, p=0.007). 
In a series of 12 patients we also measured C4d levels before and after CHT. 
Interestingly, patients with SD/PD showed a tendency for an increase in circulating C4d 
levels following CHT whereas patients with PR/MR showed a weak tendency for a 
decrease (relative differences between pre- and post-chemotherapy C4d levels: SD/PD 
+0.39±0.37 versus PR/MR -0.10±0.21 µg/mL, p=0.300). 
 
5.2.6 Circulating C4d has a prognostic impact in MPM 
As a next step, we investigated the prognostic impact of circulating plasma C4d level 
and dichotomized our cohort into patients with high (≥1.5 µg/mL; n=9) and low median 
C4d levels (<1.5 µg/mL; n=21) at time of diagnosis. Patients with high C4d had 
significantly worse prognosis compared to patients with low plasma levels (Figure 
30B). Importantly, a multivariate cox regression analysis revealed that plasma C4d 
levels at diagnosis influenced OS independently from histological subtype, IMIG stage 
and type of treatment (Table 10). 
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Table 10: Multivariate Cox-regression analyses adjusted for clinical factors influencing OS of MPM 
patients. MMT, multimodal treatment; CHT, chemotherapy; RT, radiotherapy; NA, not available; HR, 
hazard ratio; CI, confidence interval. 
    
HR 95% CI p 
Histology Epithelioid 
Non-epithelioid 
0.695 
1 0.250-1.935 0.486 
IMIG Stage Early (I/II) 
Late (III/IV) 
0.711 
1 
0.176-2.875 0.633 
Treatment MMT 
CHT and/or RT 
0.277 
1 
0.101-0.761 0.013 
Plasma C4d 
levels 
Low 
High 
0.263 
1 
0.096-0.725 0.010 
 
5.2.7 Correlation of circulating C4d and C3a levels 
C4d is the degradation product of C4 in the classical and lectin complement pathways. 
Together with C2a it forms a proteolytic convertase which cleaves C3 releasing C3a 
into the surrounding. Here, we investigated the specificity of circulating C4d as a 
representative marker for complement activation and measured plasma C3a levels in 
patients with high (n = 14) and low (n = 13) circulating C4d levels as well as in HVs (n 
= 12). In this cohort, plasma C3a levels were significantly higher in MPM patients 
compared to HVs (Figure 31A). Within the cohort of MPM patients, C3a levels did not 
correlate with histological subtype (epithelioid versus non-epithelioid: 122.70±13.01 
versus 151.50 ±22.24 µg/mL, p=0.244), stage (IMIG stage I or II versus III or IV: 
119.90±21.82 versus 144.10 ±15.69 µg/mL, p=0.406,) or age (Pearson r: -0.05; 
p=0.807). However, we found a modest but significant positive correlation between 
circulating C3a and C4d plasma levels (Figure 31B).  
Finally, to investigate whether C3a shows a similar reliability as a prognostic marker in 
MPM as C4d, we divided the selected C3a sub-cohort into low (n=14) and high (n=13) 
C3a categories by using the median plasma C3a level as a cut-off (119 ng/mL). There 
was a tendency for decreased OS in patients with increased circulating C3a (Figure 
31C). Of note, a similar tendency for worse OS in patients with high circulating C4d 
levels was found in the same subcohort (HR 2.542, CI 0.86 – 7.56, p=0.106). These data 
strongly suggest that the elevated C4d levels found in late stage MPM is the result of 
the activation of either the classical of the lectin complement activation pathway. 
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Figure 31: Plasma levels of C3a in MPM patients. (A) MPM patients had significantly higher circulating 
C3a levels compared to HVs (MPM versus HVs: Mann Whitney U test, p=0.013). (B) There was a 
modest but significantly positive correlation between circulating C3a and C4d levels (Pearson r = 0.57, 
p<0.001). (C) Kaplan-Meier survival curve of selected MPM patients with C3a plasma samples. After 
dividing the cohort (median plasma C3a as cut-off: 119 ng/mL) into sub-cohorts of patients with low 
(n=14) versus high (n=13) C3a plasma levels, there was a tendency for difference in OS between the two 
groups (C3a plasma levels >119ng/mL: HR 2.52, CI 0.75 – 8.38, p=0.117). 
 
5.2.8 Limited tumor cell-specific expression of C1q in MPM 
The classical complement activation pathway is initiated by the binding of C1q to the 
target molecule. To investigate whether circulating C4d derives from this pathway, we 
performed C1q IHC in 14 FFPE tissue specimens deriving from selected patients with 
high (n = 7) and low (n = 7) circulating C4d levels. Similar to C4d, we found no 
significant C1q expression by tumor cells. Only two MPM samples, both deriving from 
patients with low circulating C4d levels, showed weak tumor cell-specific C1q staining 
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(Figure 32A). However, inflammatory cells stained positive for C1q regardless of 
circulating C4d values (Figure 32B). Based on this observation, we next performed 
semiquantitative evaluation for tumor-associated inflammatory cells in HE-stained 
sections from the aforementioned 14 specimens and found no correlation between 
circulating C4d levels and inflammatory cell infiltration. 
 
 
Figure 32: Tissue expression of C1q in MPM. Scale bar is 50 μm. (A) Slightly positive tumor cells were 
only found in two patients (both with low circulating C4d levels). (B) Scattered positive staining (i.e. 
inflammatory cells) for C1q was found in all cases.   
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5.3 Circulating ActA as a prognostic biomarker in MPM 
5.3.1 Impact of ActA in a in distinguishing MPM from non-malignant pleural disease 
First, we evaluated circulating ActA regarding its potential to act as a diagnostic 
biomarker for distinguishing MPM from NMPD or HVs. Circulating ActA levels were 
significantly elevated compared to HVs or patients with NMPD. Patients with NMPD 
also showed a trend for elevation of ActA levels (Figure 33A).  
 
 
Figure 33: Circulating activin A levels are increased in MPM patients. A, There was a highly significant 
difference between healthy controls and patients with MPM (P < 0.0001, Bonferroni correction P = 
0.0029). Interestingly, there was also a small but significant increase in patients with pleuritis or fibrosis 
(NMPD) compared to the control group (P = 0.0067). B, A significant difference was revealed within the 
three MPM histological subtypes (P = 0.0022, Bonferroni correction P = 0.0032). Sarcomatoid patients 
had a significantly higher circulating ActA level than those with epithelioid tumours (P = 0.0019). 
Additionally, biphasic cases showed a modest but significant elevation in plasma ActA levels (P = 
0.0188). C, A significantly lower circulating activin A level was observed in patients below the median 
age (66 years) when compared to older patients (P = 0.0362). * P ≤ 0.05; *** P ≤ 0.001; MPM, malignant 
pleural mesothelioma. 
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Next, basic clinicopathological characteristics were compared using median ActA levels 
as a cut-off (Table 11 and Table 12). Patients with ActA levels below the median were 
significantly younger, of epithelioid subtype, and had lower stage and more often MMT 
including MCR (Table 11). There was a significant difference in ActA levels between 
the 3 main histological subtypes of MPM (Figure 33B). Moreover, ActA levels were 
significantly decreased in patients below the median age of 66 years (Figure 33C). 
 
Table 11: Clinicopathological characteristics of MPM patients grouped by circulating ActA level. BSC, 
best supportive care; MMT, multimodal treatment; EPP, extrapleural pneumonectomy; NA, not available; 
SD, standard deviation 
 Total ActA low ActA high p 
Gender Male 102 49 53 0.387 
Female 27 16 11 
Age Mean ± SD 65 ± 11.7 63 ± 11.6 67 ± 11.6 0.072 
Smoker  
(NA = 12) 
Never 48 26 22 0.602 
Former 45 22 23 
Current 24 10 14 
Histology  
(NA = 1) 
Epithelioid 94 54 40 0.016 
Non-epithelioid 34 11 23 
IMIG stage  
(NA = 37) 
I 7 5 2 0.049 
II 17 9 8 
III 38 23 15 
IV 30 9 21 
Treatment  
(NA = 12) 
BSC 21 9 12 0.007 
Chemo or radio 46 17 29 
MMT 50 34 16 
Surgery EPP 39 28 11 0.002 
No 90 37 53 
 
5.3.2 ActA level has prognostic impact in epithelioid MPM only 
The prognostic impact of circulating ActA was further examined by dichotomizing the 
patient cohort with reliable OS data (n = 119, median follow-up time 1028 d) by its 
median plasma ActA level (Figure 34A and Table 12). The Youden index analysis was 
performed in order to determine the best cut-off level for OS, with the highest index 
being 0.3377 at 574 pg/ml (similar to our chosen median cut-off). Patients with high 
plasma ActA levels had significantly worse outcome compared to patients with low 
levels. With regards to age, plasma ActA proved to be a prognostic marker only in 
patients under the age of 66 years (Figure 34B).   
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Table 12: Univariate survival analyses (n = 119). BSC, best supportive care; CHT, chemotherapy; RT, 
radiotherapy; MMT, multimodal treatment; OS, overall survival; CI, confidence interval; HR, hazard 
ratio; NA, not available. 
 N OS Ratio (CI) p HR (CI) 
Gender Female 25 537 0.808 (0.213–1.404) 0.353 1.264 (0.771–2.074) 
Male 94 434 
Age >66 59 408 1.316 (0.658–1.974) 0.024 0.603 (0.389–0.935) 
≤66 60 537 
Histology 
(NA = 1) 
Non-epi 32 271 2.092 (1.457–2.727) 0.001 0.399 (0.230–0.695) 
Epi 86 567 
ActA High 59 365 2.014 (1.358–2.670) 0.001 0.387 (0.247–0.606) 
Low 60 735 
Stage 
(NA = 33) 
Late 67 438 1.676 (1.132–2.220) 0.183 0.685 (0.393–1.196) 
Early 19 734 
Treatment 
(N = 12) 
BSC 20 182 0.236 (0.309-0.780) 0.001 6.756 (3.024–15.09) 
CHT/RT 44 395 0.512 (0.083-1.106) 2.901 (1.703–4.941) 
MMT 43 772 1 (0.439–1.561) 1 (0.557–1.796) 
 
Importantly, plasma ActA had a prognostic impact only in the subgroup of patients with 
epithelioid MPM (Figure 34C). In patients with non-epithelioid histology, there was a 
non-significant trend for different OS regarding ActA levels only (Figure 34D).  
 
 
Figure 34: Prognostic power of circulating plasma ActA in MPM. A, Kaplan–Meier survival analysis of 
all MPM patients (n = 119). There was a significant difference in the OS between MPM patients with low 
(n = 60, 735 d) versus high (n = 59, 365 d) circulating plasma ActA level when median plasma level was 
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used as a cutoff (574.0 pg/ml, P < 0.0001). B, The plasma level of ActA is prognostic only in patients 
younger than 66 years of age (P < 0.0001). C, Plasma level of ActA has a prognostic value in epithelioid 
MPM patients (n = 86, P = 0.0003). D, In contrast, plasma level of ActA has no impact on the OS in 
patients with non-epithelioid MPM (n = 32, P = 0.1998). MPM, malignant pleural mesothelioma; OS, 
overall survival. 
Moreover, in patients with ActA level measured at the time of diagnosis only (n = 65) 
ActA remained as a significant prognostic parameter (HR 0.57, CI 0.31–1.02, P = 
0.058). 
To assess the prognostic value of circulating ActA independently from other clinical 
parameters, we performed a multivariate analysis including age, gender, histological 
subtype and stage (Table 13). To ensure the applicability of the respective subgroup 
analysis, interaction terms for covariates were calculated for ActA and introduced to the 
multivariate cox regression model. A significant interaction term was found between 
age and plasma ActA levels (P = 0.014), whereas the interaction between histology and 
plasma ActA levels failed to reach statistical significance (P = 0.943). 
 
Table 13: Multivariate analysis by Cox regression model adjusted for patient characteristics (n = 85). CI, 
confidence interval; HR, hazard ratio. 
 
N HR P 
95% CI 
Lower Upper 
Gender Female 18 1    
Male 67 1.142 0.673 0.617 2.114 
Age >66 33 1    
≤66 52 0.750 0.284 0.443 1.270 
Histology Non-epi 19 1    
Epi 66 0.621 0.112 0.345 1.117 
ActA High 42 1    
Low 43 0.420 0.002 0.245 0.721 
Stage Late 66 1    
Early 19 0.818 0.540 0.431 1.553 
 
In this multivariate cox regression model, ActA was the only significant cofactor, 
independently influencing OS apart from gender, age, MPM subtype and stage of 
disease. 
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5.3.3 Association of circulating ActA and fibrinogen 
In a previous study, our group has demonstrated that circulating fibrinogen can act as a 
strong prognostic parameter in MPM [103]. Accordingly, we correlated ActA with 
fibrinogen levels and found a modest but significant association between these two 
parameters (Figure 35A). Furthermore, we performed a ROC curve analysis to estimate 
the predictive value of these parameters with regard to 1-year OS and found a similar 
sensitivity and specificity of both biomarkers (Figure 35B). 
 
 
 
Figure 35: Comparison of sensitivity and specificity for prognostic power of circulating ActA and 
fibrinogen by ROC curve analysis. A, A weak but significant correlation was found between fibrinogen 
and plasma ActA levels in 67 MPM patients (Spearman r = 0.37, P = 0.002). B, Circulating ActA levels 
proved to have a similar sensitivity and specificity as fibrinogen levels with an area under the curve of 
0.657 and 0.687, respectively. MPM, malignant pleural mesothelioma; ROC, receiver operating 
characteristics. 
 
5.3.4 Correlation of ActA with tumor volume and chemotherapy treatment 
Tumor volumetry analysis was performed in 19 patients and correlated with circulating 
ActA levels (Figure 36 A+B). Tumor volume showed a significant positive correlation 
with the corresponding plasma ActA levels (Figure 36C). 
In an exploratory analysis, we compared matched chemo-naïve and post-chemotherapy 
(CHT) samples (n = 14). Increased levels were found in ten patients whereas plasma 
ActA level decreased after treatment in four patients (Figure 36D). Of note, the patient 
with the dramatic decrease in plasma ActA level after CHT experienced a major 
response. 
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Figure 36: Exploratory subgroup analysis for the correlation of circulating ActA levels with tumor 
volume and cytotoxic chemotherapy. A and B, Representative CT-images from patients with a low (A) 
and high (B) tumor load. Red stars and arrows indicate the localization of the tumor lesions; ‘LU’ depicts 
the healthy lung tissue. C, Tumor volumes measured at the time of diagnosis showed a significant 
correlation with the corresponding plasma ActA values. (Spearman r = 0.548, P = 0.019). D, Matched 
chemo-naive and post-chemotherapy samples were available in 14 MPM patients. The paired t-test 
revealed a non-significant relationship between the chemo-naïve and post-chemotherapy plasma ActA 
levels (P = 0.287). CT, computed tomography; MPM, malignant pleural mesothelioma. 
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6 Discussion 
MPM is a rare but devastating disease. Despite many efforts in prevention, early 
detection, identification of prognostic parameters and new therapeutic approaches, its 
outcome is extremely dismal. Accordingly, new markers are urgently needed to guide 
selection for new therapeutic compounds and to identify patients for more aggressive 
treatment approaches. The research conducted in part within this thesis deals with the so 
far unmet need for molecular prognosticators, which might be easily available, 
reproducible and detectable and could lead to a better understanding of the underlying 
mechanisms of resistance to more aggressive multimodal treatment approaches and 
eventually to improved patient selection to avoid dismal outcome. 
 
6.1 Diagnostic biomarkers in MPM 
As has been pointed out in the introduction of this thesis, mesothelioma occurs 
unfrequently, but is still gradually on rise and previous asbestos exposure is a main risk 
factor for MPM development. In Europe, the average incidence is 0.02 per 1000 
inhabitants and the frequency is highly dependent on the amount of asbestos removal, 
asbestos import and industrialization. The peak incidence of MPM is to be expected 
between around 2020 due to the long latency period [13]. Exposure to asbestos is highly 
labor-dependent and occupations associated with exposure are traditionally carried out 
by men. This association leads to a 2 to 8-fold higher risk for MPM development in 
men, depending on the geographic region. However, asbestos exposure not only triggers 
chronic pleural inflammation to contribute to the formation of malignant mesothelial 
cells, but can also cause NMPDs such as pleuritis or chronic pleural plaques [32]. This 
leads to the frequent clinical problem of determining appropriate diagnostic strategies 
for asbestos-exposed individuals with recurrent pleural effusions or pleural thickening. 
Blood- or pleural effusion-derived diagnostic biomarkers could substantially improve 
early diagnosis by distinguishing MPM from NMPD and thus increase the potential 
chances for curative treatment attempts. Several new circulating diagnostic markers 
have recently been investigated to rule out or confirm the suspicion for MPM and to 
individualize treatment strategies. Until recently, fibulin-3, a member of the 
extracellular glycoprotein fibulin family, was the most promising biomarker for early 
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diagnosis so far. A recent study including 92 MPM patients, 136 asbestos-exposed 
individuals without cancer, 93 patients with pleural effusions due to NMPD and 43 
healthy controls from 2 different centers, investigated whether plasma and pleural 
effusion fibulin-3 could meet the criteria for a robust diagnostic biomarker [224]. In this 
study, plasma and pleural effusion fibulin-3 levels were significantly elevated compared 
to controls. ROC curve analysis for plasma fibulin-3 levels revealed a sensitivity of 
96.7% and a specificity of 95.5% at a cutoff value of 52.8 ng/ml. In early-stage MPM, 
the sensitivity was 100% and the specificity was 94.1% at a cutoff value of 46.0 ng/ml 
for distinguishing from asbestos-exposed individuals. The authors of this study 
consequently considered fibulin-3 as an excellent robust blood and effusion derived 
biomarker to early diagnose MPM in an asbestos exposed cohort and to distinguish 
between benign and malignant, MPM-associated pleural effusion. After publication of 
this study, many health care specialists, especially those dealing with occupational 
diseases, were excited about the high diagnostic power of this recently discovered 
biomarker. Unfortunately, the results could not be reproduced when applied to different 
study populations and it remains still unclear, if fibulin-3 should be routinely examined 
in patients with suspicion for MPM [225, 300]. In addition to fibulin-3, osteopontin has 
been suggested to serve as an additional diagnostic biomarker for early MPM detection. 
Osteopontin (OPN) is an extracellular matrix glycoprotein which is overexpressed in 
several human neoplasms such as lung, breast, prostate and colon cancer [301]. Seven 
studies have so far assessed the diagnostic value of OPN in MPM [302]. A recent meta-
analysis of these studies on circulating osteopontin revealed a pooled sensitivity of 0.57 
and specificity of 0.81, with an AUC of 0.8. This is clearly a lower diagnostic accuracy 
compared to fibulin-3.  
In addition to its prognostic value in MPM, plasma ActA was also investigated as a 
diagnostic marker to distinguish between HV, NMPD and MPM in the project described 
in this thesis [303]. There was a significant difference between circulating ActA levels 
when HVs (median 361.3 pg/ml, lower quartile 302.3 pg/ml, upper quartile 473.1 
pg/ml) and MPM patients (n=129, median 562.0 pg/ml, lower quartile 395.2 pg/ml, 
upper quartile 859.8 pg/ml) were compared, but no significant difference was found 
between MPM and NMPD. We observed the same finding in our project with regards to 
C4d, as it was not able to distinguish between MPM and NMPD. Both proteins (i.e. 
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ActA and C4d) are expressed in normal tissues and released into circulation but might 
also promote tumor development and progression [252, 292]. However, the precise 
molecular mechanisms of ActA and C4d synthesis related to MPM formation and 
thereby the use of these proteins as potential circulating diagnostic markers for early 
MPM detection are yet to be further investigated. Furthermore, the results derived from 
the so far most promising diagnostic biomarkers, fibulin-3 and osteopontin, warrant 
further studies in larger cohorts before these markers can be recommended for early 
MPM detection in occupationally asbestos exposed individuals in the routine practice. 
 
6.2 Prognostic factors and biomarkers in MPM 
Apart from early MPM detection, tremendous efforts have been undertaken to optimize 
patient selection for different treatment modalities in MPM patients. Routinely assessed 
clinical factors were among the first to estimate prognosis. It has been clearly shown in 
large database analyses that the expected survival for MPM patients highly depends on 
the age, gender, performance status, tumor stage and histological subtype [99, 100]. 
Epithelioid MPM has a better overall prognosis than non-epithelioid histological 
subtypes (median OS 19 months vs. 13 months (biphasic) and 8 months (sarcomatoid)) 
and thus it became clinical practice to exclude non-epithelioid cases from aggressive 
treatment approaches due to the expected poor outcome [85]. A recent phase II study 
evaluating a new multimodality approach with neoadjuvant accelerated IMRT followed 
by EPP (SMART protocol) reported benefit from treatment only in epithelioid cases, 
whereas patients with biphasic subtype had significantly poorer OS [151]. Moreover, 
analysis of the IASLC MPM database revealed a trend for improved OS after surgical 
treatment in the epithelioid subgroup only. Based on these observations, surgery is not 
routinely recommended for non-epithelioid cases according to the latest NCCN, ESMO 
or ESTS/ERS guidelines for management of MPM [81, 85, 86]. The same holds truth 
for patients in advanced disease and poor performance status.  
In recent years, a number of tissue and circulating biomarkers has been proposed in 
order to determine prognosis of different patient subgroups or biomarker-based 
treatment guidance. Usually, a protein of interest at tissue level can be easily detected 
and quantified via IHC and its expression pattern can be correlated with clinical data 
and survival. These frequently investigated markers include EGFR, c-MET, Axl, 
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Syndecan-1, NTS, CD9, CD26, AQP1, CD72, CD43, p53, COX-2, ERCC1 or TS 
(reviewed in chapter 2.1.7.) However, the majority of these studies consists of single-
center experiences, some of which may have been certainly underpowered. For some 
specific biomarkers, which were investigated by several groups, results have been 
conflicting. Differences in case distribution based on gender, histology, stage and 
treatment, as well as different methodology, have likely contributed to these 
discrepancies and larger international cooperation and tissue biobanks are needed to 
overcome these obstacles in the future. 
Ki-67 is a frequently used IHC marker to determine the fraction of proliferating cells in 
a given cell population and was increasingly used as a diagnostic tool in different tumor 
types [198]. In our above described study including MPM tissue samples from 4 
different international institutions, we found that Ki-67 index is a significant prognostic 
parameter independently from sex, age, stage, histology and treatment modality. This 
finding was observed in a test cohort including patients from 3 centers and validated in 
another cohort from a forth center. Furthermore, we found that Ki-67 assessed in MPM 
patients warrants prognostic value similar to circulating inflammatory based parameters 
including CRP, NLR and fibrinogen. 
Ki-67 proliferative index was previously investigated for diagnostic yield in FFPE cell 
blocks of pleural and peritoneal effusion, but failed to show a difference between 
reactive mesothelial hyperplasia and MPM [204]. Another recent study could 
additionally demonstrate that high Ki-67 tissue expression was related to significantly 
shorter PFS and OS in chemonaive patients and remained associated with shorter PFS 
and OS after chemotherapy [187]. Importantly, our study revealed for the first time that 
Ki-67 index is only prognostic in the epithelioid but not in the non-epithelioid subgroup 
of MPM. Non-epithelioid tumors are generally associated with worse prognosis due to 
early disease progression. The underlying mechanisms of reduced prognostic influence 
of tumor proliferation in biphasic and sarcomatoid MPM remain uncovered yet.  In line 
with a previous study, however, we did not observe a significant difference in the 
proportion of Ki-67 positive tumor cells between the epithelioid and non-epithelioid 
histology, suggesting that the poor prognosis in biphasic/sarcomatoid tumors is not 
directly associated with high proliferation rates [304]. In our study, Ki-67 showed a 
non-significant association with more advanced disease stage, but not with other clinical 
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characteristics, such as gender or age. However, in subgroup analyses, Ki-67 revealed 
significant prognostic power in early and late stage patients, suggesting that Ki-67 
expression does not simply reflect clinically undetected late stage of disease.  
Our study additionally demonstrated that the prognostic impact of Ki-67 index is similar 
to other recently investigated inflammation-based circulating biomarkers [102, 103, 
298]. According to our observation, the AUC of Ki-67 in predicting 1-year OS was 
0.70. Importantly, there was a strong correlation between fibrinogen and CRP, 
suggesting that these two acute phase proteins reflect the same biological characteristics 
of MPM patients. Additionally, CRP, fibrinogen and NLR showed similar predictive 
values compared to Ki-67 index in the ROC curve analysis, suggesting similar 
biological importance during disease progression. 
Here, we also report that Ki-67 expression significantly differs between MPM patients 
undergoing different treatment regimens. Expression was significantly lower in the 
multimodality group. However, in this subset of patients, a high number of cases 
received platinum-based induction CHT, which induces cell death in tumors with highly 
proliferating cells. We have additionally shown that Ki-67 index is significantly higher 
in pre- compared to post-induction cases, suggesting reduced cell proliferation after 
CHT. This observation was also reported in a previous study [187]. Thus, we believe 
that Ki-67 index might also serve as a clinically useful marker to assess the biological 
efficacy of (induction) CHT. Of note, induction CHT was recently shown to be an 
additional important prognostic factor for MPM in a multicenter study [146]. In another 
subgroup analysis, we demonstrate here that Ki-67 had prognostic impact in patients 
undergoing surgery and in those with conservative treatment (i.e. systemic treatment or 
BSC), suggesting that this marker might be useful for selecting patients both in surgical 
and conservative treatment arms. In the multivariate cox regression model, Ki-67 
remained as a significant prognostic variable for OS, independently from other clinical 
parameters. In addition, histological subtype (i.e. epithelioid vs. non-epithelioid) and 
treatment modality had an independent influence on survival, which is well in line with 
other previous reports on prognostic factors in larger MPM cohorts [8, 100, 142]. 
Moreover, the rather historical subgroup of patients undergoing a surgery-only approach 
tended to have significantly shorter OS compared with patients who receive 
multimodality treatment. This observation has been previously reported by a number of 
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other high-volume centers and thus the strategy to perform surgery exclusively within a 
multimodality approach is well perceived among MPM specialists worldwide [8, 100, 
139]. Our multicenter study strongly supports this approach. 
The feasibility, importance and application of certain tissue-derived biomarkers as 
prognostic factors in MPM have been well established. The tissue needed for analysis, 
however, obviously has to be retrieved at the time of diagnosis. Yet, tissue biopsy can 
be quite challenging. VATS biopsy usually obtains large tissue samples for diagnosis 
and investigation of additional markers, but this applies for patients only that are 
candidates for surgery. In unresectable cases due to poor PS or advanced tumor stage, 
CT-guided biopsy is the diagnostic method of choice and hence tumor tissue might be 
consumed for establishing definite diagnosis but might not be available for additional 
investigations (i.e. for further molecular profiling). 
Taken this into account, blood-derived prognostic biomarkers represent an important 
tool to overcome the common lack of tissue availability. Furthermore, they can be easily 
retrieved and simply reassessed at multiple time points. Some of the reported blood 
biomarkers are actually commonly assessed during routine investigations. These include 
white and red blood cell and thrombocyte counts, and more recently, NLR, PLR and the 
modified Glasgow Prognostic Score (GPS), consisting of CRP and its negative acute 
phase response counterpart albumin [209]. Our study group has additionally shown the 
prognostic significance of acute phase proteins such as CRP and fibrinogen [102, 103]. 
Some of these markers have even shown to be able to predict benefit from certain 
treatment modalities. Accordingly, these molecules can be useful in allocating patients 
to multimodality approaches. The majority of these markers might reflect the burden of 
the disease and are clearly associated with stage and PS, however, are not directly 
associated with malignant cells. In recent years, research has increasingly focused on 
tumor-associated circulating biomarkers, which might have therapeutic impact in the 
future. Among these, drugs against circulating VEGF, mesothelin or fibulin-3 have been 
investigated for their therapeutic value [84, 213, 218, 224, 305, 306].  
Today, there is increasing evidence that the complement system is not only an important 
player within the inert immune system but is also involved in cancer development and 
progression by facilitating cellular proliferation and regeneration by a variety of 
mechanisms [226]. However, molecular mechanisms of complement protein-associated 
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MPM formation and progression had not been investigated before. Nevertheless, it has 
been shown that C4d, the stable cleavage product of complement protein C4, 
accumulating following classical and lectin pathway activation, might play a role in 
various tumor types including MPM [254, 255]. Although MPM development is 
strongly associated with chronic asbestos-related inflammation, complement activation 
in human MPM was barely understood and thus no study had focused on the prognostic 
or predictive role of C4d as a marker for complement activation in this disease. Thus, 
the aim of the study described in this thesis was to investigate the tissue and circulating 
levels of C4d in MPM patients and to compare these data with tumor load, 
chemotherapy response and clinicopathological parameters. Importantly, we found that 
late-stage MPM patients had higher plasma C4d levels and high circulating C4d was 
associated with a higher tumor volume. Plasma C4d levels following induction 
chemotherapy were significantly higher in patients with SD/PD and patients with low 
C4d levels at diagnosis had a significantly better OS as confirmed in a multivariate cox 
regression model. To the best of our knowledge, our study was the first to indicate the 
prognostic relevance of plasma C4d in MPM. 
Of note, in our cohort, C4d plasma levels were lower compared to LADC patients from 
previous studies and thus we used 1.5 µg/mL as a cut-off in our cohort in contrary to the 
3.0 µg/mL used by others. Lung cancer cells were shown to be able to directly activate 
the classical complement pathway via C1q binding, suggesting higher circulating levels 
of complement activation proteins [248]. Circulating C4d levels in MPM patients 
showed similar prognostic power for OS, comparable to other well-established 
biomarkers in thoracic tumors [102, 103, 294, 303, 307, 308]. However, we did not 
observe a significant difference in C4d levels between MPM patients and HVs or 
patients with NMPD and thus C4d may not be used as a diagnostic marker in this 
disease. 
In contrast to LADC, MPM cells did not positively stain for C4d by IHC. Of note, C4d 
tumor expression was found to correlate with prognosis, disease-stage and/or nodal 
invasion in a variety of other tumor types [248, 249, 252, 254]. However, IHC staining 
for C4d did not reveal tumor specific expression in lymphoma cells [309]. Hence, this 
lack of C4d expression in MPM cells might suggest that the complement cascade does 
not get directly activated by malignant cells. Importantly, we found C4d expression in 
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the germinal centers of intratumoral ectopic lymphoid structures. Accordingly, as has 
been described within this thesis, circulating C4d was also associated with other 
inflammatory-based markers including CRP and fibrinogen.  
In the classical complement pathway, C1q activates C4. Accordingly, we analyzed the 
staining pattern of C1q and found a modest tumor cell specific C1q expression only. 
This is in line with a previous study on transcriptome analyses of MPM cell lines, 
demonstrating the up-regulation of C1q-binding protein (a negative regulator of C1q) 
[310]. However, C1q was clearly expressed in tumor-infiltrating immune cells. Whether 
these infiltrating immune cells themselves express C1q or the expression is related to 
tumor associated complement activation remains unclear and could not be uncovered by 
our study. 
As has been reported in LADC [248], we observed a correlation of C4d and disease 
stage in our cohort. Of note, tumor tissue-specific expression of C4d was shown to 
additionally correlate with stage and tumor size in oral squamous cell carcinoma and 
astrocytomas [249, 254]. However, the correlation between tumor load and circulating 
C4d has not been studied. Accordingly, our study is the first to show a correlation 
between circulating C4d levels and tumor volume assessed by CT-scans. Our results 
suggest that a more advanced disease as well as a higher local tumor load might lead to 
amplification of complement activation resulting in opsonization of malignant cells. We 
further hypothesize that not MPM tumor cells themselves but the local immune 
infiltrative cells might trigger the activation of the complement cascade. The increase in 
tumor load during disease progression might be related to a higher amount of immune 
cell infiltration resulting ultimately in higher circulating complement activation 
proteins.  
In our study, we further investigated the specificity of circulating C4d as a marker for 
complement activation in MPM and consequently measured plasma C3a levels in 
corresponding patients. Similar to C4d, C3a is a complement-specific cleavage product 
and can be induced by all three complement activation pathways. Accordingly, it is a 
very unspecific marker for complement activation. In contrast to C4d, C3a levels were 
increased in MPM patients compared to HVs and there was a modest correlation 
between C3a and C4d only. C3a showed a prognostic significance, similar to C4d. 
These findings further support the presence of complement activation in certain MPM 
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patients and underline the clinical role of complement activation in MPM. It is 
important to note that while the investigation of the additional markers C3a and C1q 
contributes to establishing the specificity of C4d as a biomarker, these correlative 
studies cannot dissect the upstream events and thus the specific mechanisms of 
complement activation in MPM.  Further studies, including preclinical in vitro and in 
vivo experiments, are needed to identify the specific complement activation pathways 
that contribute to the progression of MPM.  
To date, no blood derived biomarker exists in order to differentiate between histological 
MPM subtypes [311]. In line with other studies on blood biomarkers, in our study, C4d 
levels tended to be modestly higher in non-epithelioid patients, with no significant 
difference [217, 303, 311, 312].  
Here, importantly, we had the opportunity to correlate C4d with chemotherapeutic 
response to CHT. Remarkably, patients with progression after CHT treatment had 
significantly higher C4d levels when compared to those with treatment response. Thus, 
we concluded that investigating C4d levels may help re-staging and re-evaluation of 
patients following induction CHT before surgical intervention. This is of importance, 
since response evaluation and examining tumor expansion by RECIST criteria remains 
challenging in MPM [255, 313].  
So far, our study is the first to report that circulating C4d levels directly correlate with 
primary tumor load, chemotherapeutic response and OS in MPM. Therefore, 
additionally to conventional response assessment, measuring C4d levels might aid re-
staging in order to estimate individual treatment efficacy more comprehensively. 
 
In the last part of this thesis, we demonstrate that circulating ActA can serve as an 
additional prognostic biomarker in MPM. Our group has recently shown that MPM cells 
overexpress ActA [292] and, moreover, that ActA exposure causes increased 
proliferation and migration whereas inhibition of activin receptors decreases MPM cell 
growth and survival. Thus, in MPM, similar to reports in NSCLC [294] and esophageal 
carcinoma [295, 296], ActA is associated with malignant behavior. Moreover, our group 
has recently shown that circulating ActA levels are elevated compared to healthy 
controls and correlated with disease stage and survival in LADC [297]. However, no 
data were available on the impact of circulating ActA levels in MPM. 
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As described above, in our study, circulating ActA levels were significantly increased in 
MPM patients when compared to HVs. Non-epithelioid cases were associated with high 
ActA levels when compared to epithelioid histology. As has been described for C4d, 
also tumor volume showed a positive correlation with increased circulating ActA levels. 
MPM patients with low ActA levels exhibited significantly improved OS, being 
exclusively prognostic in epithelioid cases. 
As mentioned, no circulating biomarker has been reported to reliably distinguish 
between histological subtypes of MPM. Importantly, in our study, we found an 
association between ActA levels and non-epithelioid subtypes. Previously, as has been 
described above, also blood derived fibulin-3 showed no correlation with histological 
MPM subtypes [224]. However, effusion derived fibulin-3 was significantly increased 
in non-epithelioid MPM. Due to the relatively small number of non-epithelioid cases in 
this study, the potential diagnostic impact of ActA should be further evaluated in larger 
cohorts with increased numbers of biphasic and sarcomatoid cases.  
In our cohort, we demonstrated a correlation of circulating ActA levels with increased 
age. Of note, accordingly, ActA was prognostic only in patients aged 66 years or 
younger. However, in an additional multivariate analysis, we found the interaction term 
between ActA and age to be significant. 
Nevertheless, plasma ActA levels were highly prognostic in this large multi-center 
cohort analysis. By using the cox regression model, we also confirmed that low 
circulating ActA is an independent prognostic factor associated with better OS in MPM 
patients. 
A previous study from our group identified fibrinogen as a novel prognostic biomarker 
in MPM [103]. Our correlation analysis revealed a significant relationship between 
ActA and fibrinogen. Moreover, fibrinogen and ActA levels demonstrated a similar 
prognostic power in predicting 1-year OS when ROC curve analysis was performed. 
Furthermore, in contrast to ActA, fibrinogen did not tend to be elevated in non-
epithelioid cases in our previous study. 
In contrast to several other investigated biomarkers (including C4d), the biological 
function of ActA has been well described and ActA was shown to exert protumorigenic 
effects in several cancer types including MPM. Currently, novel inhibitors of the activin 
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signaling cascade are being investigated for use in a variety of diseases [281]. 
Accordingly, it may represent a novel therapeutic target in MPM. 
Hence, our findings suggest that the measurement of circulating ActA may support the 
histological classification of MPM and at the same time help to identify epithelioid 
MPM patients with poor prognosis. 
 
In summary, this thesis deals with the emerging but yet unmet need for diagnostic, 
prognostic and predictive biomarkers in MPM. We could additionally demonstrate that 
an international cooperation is needed to establish larger tissue and data collections to 
study this rare disease in depth. Only a tight integration of translational research from 
bed to bench and vice versa will allow researchers to effectively investigate new 
compounds and guide therapy individually using reliable and reproducible biomarkers. 
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7 Conclusion 
Considering the results of this thesis, the following main conclusions can be drawn in 
order to answer the questions as formulated in the aims of the thesis. 
 
1. Ki-67 index is a reproducible and easily available prognostic tissue derived 
biomarker in MPM. We could demonstrate that high Ki-67 expression is associated 
with significantly worse prognosis in a large international tissue collection and this 
result was additionally reproduced in an independent validation cohort. Importantly, 
Ki-67 was exclusively prognostic for OS in epithelioid MPM. Moreover, we showed 
that chemotherapy significantly decreased tumor proliferation (as measured by Ki-67 
expression) in MPM and thus Ki-67 might be used as marker to monitor response to 
chemotherapy. 
 
2. Complement activation might play a role in the formation and progression of MPM. 
Here we report for the first time that C4d, a marker for complement cascade 
activation, is significantly elevated in late stage MPM and patients with high tumor 
volume. Furthermore, high circulating C4d levels were significantly associated with 
lack of clinical response to chemotherapy and with decreased OS. Considering these 
results, we suggest that compliment activation plays an important role in MPM, 
partly influencing prognosis. We also conclude that assessing circulating C4d levels 
might help to select patients for surgery following induction chemotherapy. 
 
3. The biological function and protumorigenic effect of ActA in MPM has been well 
described. In our study we demonstrate that circulating ActA is significantly elevated 
in MPM, especially in cases with non-epithelioid subtype. As in the case of C4d, 
high circulating ActA was associated with tumor volume and worse prognosis. 
Similar to Ki-67 index of MPM tissue, circulating ActA was exclusively prognostic 
in epithelioid cases. In summary, circulating ActA may support the histological 
classification of MPM and at the same time help to identify epithelioid MPM patients 
with poor prognosis. 
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8 Summary 
Objective: Malignant pleural mesothelioma (MPM) is a rare but devastating disease. 
Despite many efforts in prevention, early detection, identification of prognostic 
parameters and new therapeutic approaches, outcome is extremely dismal. Accordingly, 
new markers are urgently needed to guide selection for new therapeutic compounds and 
to identify patients for more aggressive treatment approaches. The aim of these works 
was to study selected tissue and blood derived biomarkers with regard to their 
diagnostic and prognostic value in a large international cohort of MPM cases. 
Methods: Due to our international cooperation, we could collect tissue, blood and 
clinical data from 5 specialized MPM centers (4 in Europe, 1 in Australia). The 
collected biological material also included tissue and blood samples from healthy 
volunteers and patients with non-malignant pleural diseases. We investigated the 
diagnostic and prognostic role of the following proteins: Ki-67, complement 
degradation product 4 (C4d) and Activin A (ActA). 
Results: We found that circulating ActA is significantly elevated in MPM cases 
compared to healthy controls and in non-epithelioid versus epithelioid tumors. Tissue 
expression of Ki-67 and circulating C4d did not show such associations. Importantly, 
expression of Ki67 was significantly lower in patients after chemotherapy. We found no 
C4d expression by tumor cells, but within intratumoral ectopic lymphoid structures. 
However, circulating C4d was significantly elevated in late stage MPM and in patients 
with high tumor volume. Furthermore, C4d was significantly associated with lack of 
clinical response to chemotherapy. Elevated ActA was additionally associated with high 
tumor volume. All three investigated biomarkers significantly influenced overall 
survival, independently from clinical variables such as age, gender, stage and 
histological subtype. However, Ki-67 and ActA revealed to be prognostic exclusively in 
patients with epithelioid subtype.  
Conclusion: These analyses of large international MPM patient cohorts demonstrate 
that 1.\ Ki-67 index is an independent and reproducible prognostic factor in epithelioid 
MPM 2.\ induction chemotherapy decreases the proliferative capacity of MPM. 3.\ 
circulating plasma C4d is a promising new prognostic biomarker in MPM and it may 
help to select patients for surgery following induction chemotherapy and 4.\ ActA may 
support the histological classification of MPM and at the same time can help to identify 
epithelioid MPM patients with poor prognosis. 
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9 Összefoglalás 
Célkitűzés: A malignus pluerális mesothelioma (MPM) egy ritka, de rendkívül rossz 
prognózisú betegség. Annak ellenére, hogy igen nagy erőfeszítéseket tesznek a 
prevenció, a korai felismerés, a prognosztikai faktorok felfedezése és új kezelési módok 
kifejlesztésének területén, a túlélési adatok lesújtóak. Éppen ezért sürgős szükség van új 
markerek felfedezésére, amelyek segíthetnek célzott hatóanyagok előállításában és azon 
betegek kiválasztásában, akiknél agresszívabb kezelési mód szükséges.  Kutatásaink 
célja az volt, hogy megvizsgáljuk bizonyos szöveti és keringő biomarkerek 
diagnosztikus és prognosztikus értékét egy nagy, nemzetközi MPM kohortban. 
Módszerek: Nemzetközi együttműködésünknek köszönhetően 5 specializált MPM 
centrumból (4 európai, 1 ausztrál) tudtunk szövet- és vérmintákat, valamint klinikai 
adatokat gyűjteni. Ezek részét képezték egészséges önkéntesekből és nem-malignus 
pleurális betegségben szenvedő páciensekből gyűjtött szövet- és vérminták is. A 
következő fehérjék diagnosztikus és prognosztikus szerepét vizsgáltuk: Ki-67, 
complement degradációs termék 4 (C4d) és Activin A (ActA). 
Eredmények: Vizsgálatainkban megfigyeltük, hogy a keringő ActA szignifikánsan 
emelkedettebb MPM esetekben, mint egészséges kontrol személyekben, valamint, hogy 
az ActA szint magasabb nem-epitheloid tumoros esetekben (vs. epitheloid MPM). A Ki-
67 szöveti expressziója és a keringő C4d nem mutatott hasonló összefüggést. Fontos 
megfigyelésünk volt azonban, hogy a Ki67 index szignifikánsan alacsonyabbnak 
bizonyult olyan betegekben, akik már kemoterápiában részesültek. Szemben a 
tumorsejtekkel, C4d expresszió intratumorálisan csak ectopiás lymphaticus 
struktúrákban volt megfigyelhető. Ennek ellenére a keringő C4d szintje szignifikánsan 
magasabb volt előrehaladott MPM esetekben, akikben nagy tumor-térfogat volt jelen. 
Továbbá szignifikánsan összefüggés volt kimutatható a C4d szintje és a kemoterápiára 
mutatott rossz klinikai válasz között. A növekedett ActA szintén összefüggést mutatott 
a nagy tumormérettel. Mind a három megvizsgált biomarker befolyásolta a túlélést, a 
klinikai változóktól (életkor, nem, a betegség stádiuma és pontos szövettana) 
függetlenül. Azonban a Ki-67 és ActA kizárólag epitheoild szövettani szubtípusban 
bizonyult prognosztikus értékűnek.  
Konklúziók: Ezek a nagy és nemzetközi kohorton végzett vizsgálatok bizonyítják, hogy 
1. \ A Ki-67 index egy független és reprodukálható prognosztikus faktor epitheloid 
MPM-ben, 2. \ Az indukciós kemoterápia csökkenti a MPM proliferációs képességét, 3. 
\ a keringő plazma C4d egy ígéretes új biomarker MPM-ben mely segíthet azon betegek 
kiválasztásában, akiknél érdemes operációt végezni indukciós kemoterápiát követően, 
és 4. \ ActA támogathatja az MPM szövettani klasszifikációját és egyben segíthet a 
rossz prognózisú epitheloid MPM esetek identifikálásában.  
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